[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 112209
1. Stravitz RT: Management of the Cirrhotic Patient Before Liver Transplantation: The Role of the Referring Gastroenterologist. Gastroenterol Hepatol (N Y); 2006 May;2(5):346-354

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of the Cirrhotic Patient Before Liver Transplantation: The Role of the Referring Gastroenterologist.
  • The referral of a patient with cirrhosis to a liver transplant center for evaluation is usually made by a local gastroenterologist.
  • The role of the referring gastroenterologist begins with early identification and modification of high-risk behaviors, which may delay listing a patient for liver transplantation.
  • The local gastroenterologist must also fully appreciate what constitutes a timely referral of a patient to a liver transplant center and the consequences of late referral.
  • Although patients experience the inevitable deterioration of their liver function, which in turn advances their priority on the liver transplant waiting list, the referring gastroenterologist must also anticipate medical complications of cirrhosis, and should initiate appropriate surveillance and prophylaxis programs to detect and prevent these complications.
  • Adherence to these guidelines will increase the probability that a patient with chronic liver failure will undergo successful liver transplantation and will decrease post-transplant morbidity.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Hepatol. 2003 Aug;39(2):208-14 [12873817.001]
  • [Cites] Lancet. 2003 Nov 29;362(9398):1819-27 [14654322.001]
  • [Cites] J Hepatol. 2003 Jan;38(1):51-8 [12480560.001]
  • [Cites] Gastroenterology. 2003 Sep;125(3):937-40 [12949737.001]
  • [Cites] Gastroenterology. 1987 Aug;93(2):234-41 [3297907.001]
  • [Cites] Hepatology. 1990 Aug;12(2):273-80 [2391068.001]
  • [Cites] Semin Liver Dis. 2005;25(2):181-200 [15918147.001]
  • [Cites] Hepatology. 1992 Jul;16(1):132-7 [1352268.001]
  • [Cites] Am J Gastroenterol. 2002 Feb;97(2):435-9 [11866284.001]
  • [Cites] Hepatogastroenterology. 1997 Jul-Aug;44(16):1172-81 [9261620.001]
  • [Cites] Hepatology. 1995 Oct;22(4 Pt 1):1171-4 [7557868.001]
  • [Cites] Am J Gastroenterol. 2002 Mar;97(3):734-44 [11922571.001]
  • [Cites] Scand J Gastroenterol. 1987 Jan;22(1):117-23 [3563404.001]
  • [Cites] J Hepatol. 2003 Mar;38(3):266-72 [12586291.001]
  • [Cites] Liver Transpl. 2005 Mar;11(3):249-60 [15719412.001]
  • [Cites] Semin Liver Dis. 2005;25(2):201-11 [15918148.001]
  • [Cites] Semin Liver Dis. 2005;25(2):143-54 [15918143.001]
  • [Cites] Hepatology. 2001 Feb;33(2):464-70 [11172350.001]
  • [Cites] Liver Transpl. 2005 Jun;11(6):679-83 [15915490.001]
  • [Cites] Gut. 1982 Jan;23(1):1-7 [7035298.001]
  • [Cites] Drugs. 1995 Mar;49(3):467-84 [7774516.001]
  • [Cites] Hepatology. 1995 Sep;22(3):753-8 [7657279.001]
  • [Cites] J Hepatol. 1986;3(1):75-82 [3745889.001]
  • [Cites] Hepatology. 2005 Jun;41(6):1407-32 [15880505.001]
  • [Cites] J Hepatol. 2005;42 Suppl(1):S65-74 [15777574.001]
  • [Cites] Liver Transpl. 2005 Feb;11(2):124-33 [15666386.001]
  • [Cites] Hepatology. 2004 Mar;39(3):841-56 [14999706.001]
  • [Cites] Hepatology. 2002 Jan;35(1):105-9 [11786965.001]
  • [Cites] Clin Liver Dis. 2001 Aug;5(3):645-63 [11565135.001]
  • [Cites] Hepatology. 2001 Jul;34(1):28-31 [11431730.001]
  • [Cites] Gastroenterology. 2003 Sep;125(3):941-66 [12949738.001]
  • [Cites] N Engl J Med. 1988 Oct 13;319(15):983-9 [3262200.001]
  • [Cites] Am J Transplant. 2003 Dec;3(12):1481-7 [14629278.001]
  • [Cites] Hepatology. 1997 Jan;25(1):63-70 [8985266.001]
  • [Cites] Gut. 1979 Feb;20(2):133-6 [311747.001]
  • [Cites] Liver Transpl. 2002 Jul;8(7):582-7 [12089709.001]
  • [Cites] Liver. 1999 Jun;19(3):188-92 [10395037.001]
  • [Cites] Miner Electrolyte Metab. 1993;19(6):362-7 [8164617.001]
  • [Cites] Alcohol Clin Exp Res. 2004 Mar;28(3):468-79 [15084905.001]
  • [Cites] Semin Liver Dis. 1999;19(4):439-55 [10643628.001]
  • [Cites] Hepatology. 1994 Jan;19(1):72-9 [8276370.001]
  • [Cites] Ann Intern Med. 1989 May 15;110(10):838-9 [2712463.001]
  • [Cites] Gastroenterology. 2004 Nov;127(5 Suppl 1):S108-12 [15508073.001]
  • [Cites] N Engl J Med. 1998 Jan 29;338(5):286-90 [9445408.001]
  • [Cites] Am J Gastroenterol. 2003 Oct;98(10):2268-74 [14572578.001]
  • [Cites] Gastroenterology. 2004 Nov;127(5):1372-80 [15521006.001]
  • [Cites] Gastroenterology. 2003 Jan;124(1):91-6 [12512033.001]
  • [Cites] Am J Gastroenterol. 1999 Aug;94(8):2193-7 [10445549.001]
  • [Cites] Ann Pharmacother. 2005 Jan;39(1):68-76 [15590870.001]
  • [Cites] Hepatology. 1990 Oct;12(4 Pt 1):716-24 [2210673.001]
  • [Cites] Am J Gastroenterol. 2001 Jul;96(7):1968-76 [11467622.001]
  • [Cites] Gastroenterology. 2004 Nov;127(5 Suppl 1):S27-34 [15508094.001]
  • [Cites] J Gastroenterol Hepatol. 2002 Apr;17(4):462-6 [11982728.001]
  • [Cites] Clin Liver Dis. 2001 Aug;5(3):665-76 [11565136.001]
  • [Cites] Gastroenterology. 1992 May;102(5):1680-5 [1568578.001]
  • [Cites] Hepatology. 1995 Aug;22(2):432-8 [7543434.001]
  • [Cites] Dig Dis Sci. 2001 Dec;46(12):2752-7 [11768269.001]
  • [Cites] Ann Intern Med. 1995 Apr 15;122(8):595-8 [7887554.001]
  • [Cites] Gastroenterology. 2004 Apr;126(4):1005-14 [15057740.001]
  • [Cites] Gastroenterology. 1997 Aug;113(2):579-86 [9247479.001]
  • [Cites] J Cancer Res Clin Oncol. 2004 Jul;130(7):417-22 [15042359.001]
  • [Cites] Ann Intern Med. 1970 Sep;73(3):393-6 [5455989.001]
  • [Cites] Am J Gastroenterol. 2000 Sep;95(9):2343-51 [11007240.001]
  • [Cites] Hepatology. 2004 Jul;40(1):65-72 [15239087.001]
  • [Cites] N Engl J Med. 1999 Apr 1;340(13):988-93 [10099140.001]
  • [Cites] Gastroenterology. 1999 Aug;117(2):414-9 [10419924.001]
  • [Cites] Proc Soc Exp Biol Med. 1999 Nov;222(2):99-112 [10564534.001]
  • [Cites] Gastroenterology. 1981 Apr;80(4):800-9 [6970703.001]
  • [Cites] Hepatology. 2004 Mar;39(3):739-45 [14999692.001]
  • [Cites] Gastroenterology. 1980 Mar;78(3):512-7 [7351289.001]
  • [Cites] Liver Transpl. 2000 Jul;6(4):440-2 [10915165.001]
  • [Cites] Am J Gastroenterol. 2000 Feb;95(2):503-8 [10685758.001]
  • [Cites] Transplantation. 2001 Aug 27;72(4):666-70 [11544428.001]
  • [Cites] Hepatology. 1988 Jul-Aug;8(4):966-8 [3391524.001]
  • (PMID = 28289338.001).
  • [ISSN] 1554-7914
  • [Journal-full-title] Gastroenterology & hepatology
  • [ISO-abbreviation] Gastroenterol Hepatol (N Y)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; Cirrhosis / liver failure / liver transplantation / portal hypertension
  •  go-up   go-down


2. Mouralidarane A, Lin CI, Suleyman N, Soeda J, Oben JA: Practical management of the increasing burden of non-alcoholic fatty liver disease. Frontline Gastroenterol; 2010 Oct;1(3):149-155

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Practical management of the increasing burden of non-alcoholic fatty liver disease.
  • Obesity-induced liver disease (non-alcoholic fatty liver disease (NAFLD)) describes a spectrum from steatosis through steatohepatitis to cirrhosis.
  • Its prevalence is rising in tandem with societal rates of obesity which through consequent insulin resistance and fat deposition in hepatocytes lead to hepatocyte death and attempts at repair, which if persistent, lead to activation of liver fibrogenic cells.
  • NAFLD, which may also progress to primary liver cancer, is now the most common cause of chronic liver disease in affluent countries.
  • There is currently no single accurate diagnostic test besides a liver biopsy.
  • The decision to consider a liver biopsy will be informed by the presence of insulin resistance determined by comparatively easy-to-measure factors together with other putative markers of progression such as hypertension.
  • If a liver biopsy is performed, patients with steatosis with no evidence of inflammation may be less aggressively managed while those with steatohepatitis, since they have a faster trajectory to cirrhosis, should be managed more robustly.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Drugs. 2003;63(22):2379-94 [14609346.001]
  • [Cites] J Clin Invest. 2005 May;115(5):1298-305 [15864349.001]
  • [Cites] Hepatology. 2003 Apr;37(4):917-23 [12668987.001]
  • [Cites] Semin Diagn Pathol. 2005 Nov;22(4):330-8 [16939061.001]
  • [Cites] Nat Med. 2000 Sep;6(9):998-1003 [10973319.001]
  • [Cites] Hepatology. 2004 Jul;40(1):46-54 [15239085.001]
  • [Cites] Rev Gastroenterol Disord. 2002;2(1):11-9 [12122975.001]
  • [Cites] Liver Int. 2007 Mar;27(2):215-9 [17311616.001]
  • [Cites] Gastroenterology. 1994 Oct;107(4):1103-9 [7523217.001]
  • [Cites] Obes Res. 2005 Jul;13(7):1180-6 [16076987.001]
  • [Cites] Hepatology. 1995 Dec;22(6):1714-9 [7489979.001]
  • [Cites] Ann Intern Med. 2000 Jan 18;132(2):112-7 [10644271.001]
  • [Cites] Biochem Biophys Res Commun. 2003 Aug 22;308(2):284-92 [12901866.001]
  • [Cites] J Hepatol. 2007 Oct;47(4):556-64 [17459514.001]
  • [Cites] Hepatology. 2004 Mar;39(3):770-8 [14999696.001]
  • [Cites] Am J Clin Nutr. 2003 Jan;77(1):43-50 [12499321.001]
  • [Cites] J Clin Gastroenterol. 2006 Mar;40 Suppl 1:S39-43 [16540766.001]
  • [Cites] Gut. 2004 Mar;53(3):438-45 [14960531.001]
  • [Cites] Am J Gastroenterol. 2003 May;98(5):960-7 [12809815.001]
  • [Cites] J Hepatol. 2007 Apr;46(4):628-34 [17258346.001]
  • [Cites] Diabetes Care. 2001 Feb;24(2):412 [11213906.001]
  • [Cites] Hepatology. 2007 Jun;45(6):1366-74 [17476695.001]
  • [Cites] J Hepatol. 2009 Jan;50(1):204-10 [19014878.001]
  • [Cites] Gastroenterology. 2002 Jul;123(1):134-40 [12105842.001]
  • [Cites] JAMA. 2003 Jan 1;289(1):76-9 [12503980.001]
  • [Cites] Hepatology. 2005 Jul;42(1):44-52 [15895401.001]
  • [Cites] Aliment Pharmacol Ther. 2004 Jul 1;20(1):23-8 [15225167.001]
  • [Cites] Hepatology. 2005 Jun;41(6):1313-21 [15915461.001]
  • [Cites] Aviat Space Environ Med. 1984 Jan;55(1):59-61 [6696696.001]
  • [Cites] J Gastroenterol Hepatol. 1992 Sep-Oct;7(5):469-72 [1391727.001]
  • [Cites] J Hepatol. 2001 Aug;35(2):195-9 [11580141.001]
  • [Cites] J Hepatol. 2010 Jun;52(6):913-20 [20413174.001]
  • [Cites] Mayo Clin Proc. 1980 Jul;55(7):434-8 [7382552.001]
  • [Cites] Clin Gastroenterol Hepatol. 2004 Dec;2(12):1107-15 [15625656.001]
  • [Cites] Obesity (Silver Spring). 2007 Sep;15(9):2190-9 [17890486.001]
  • [Cites] Gastroenterology. 2009 Aug;137(2):532-40 [19409898.001]
  • [Cites] N Engl J Med. 2000 Nov 16;343(20):1467-76 [11078773.001]
  • [Cites] J Clin Gastroenterol. 2002 Mar;34(3):255-62 [11873108.001]
  • [Cites] Hum Pathol. 1997 Aug;28(8):953-9 [9269832.001]
  • [Cites] Am J Physiol Endocrinol Metab. 2005 Feb;288(2):E462-8 [15339742.001]
  • [Cites] Hepatology. 2007 Oct;46(4):1101-7 [17661371.001]
  • [Cites] Gastroenterology. 2004 Feb;126(2):460-8 [14762783.001]
  • [Cites] Gastroenterology. 1998 Feb;114(2):311-8 [9453491.001]
  • [Cites] N Engl J Med. 2001 Feb 15;344(7):495-500 [11172192.001]
  • [Cites] J Hepatol. 2008;48 Suppl 1:S104-12 [18304679.001]
  • [Cites] Hepatology. 2006 Oct;44(4):865-73 [17006923.001]
  • [Cites] Gastroenterology. 1999 Jun;116(6):1413-9 [10348825.001]
  • [Cites] Semin Liver Dis. 2001;21(1):3-16 [11296695.001]
  • [Cites] J Hepatol. 1996 Feb;24(2):200-8 [8907574.001]
  • [Cites] N Engl J Med. 2010 May 6;362(18):1675-85 [20427778.001]
  • [Cites] Clin Liver Dis. 2009 Nov;13(4):667-88 [19818312.001]
  • [Cites] N Engl J Med. 2000 Apr 27;342(17):1266-71 [10781624.001]
  • [Cites] Gastroenterology. 2005 Jul;129(1):113-21 [16012941.001]
  • [Cites] Clin Gastroenterol Hepatol. 2004 Dec;2(12):1048-58 [15625647.001]
  • [Cites] Hepatology. 2004 Dec;40(6):1387-95 [15565570.001]
  • [Cites] Hepatology. 1990 Jan;11(1):74-80 [2295475.001]
  • [Cites] Gastroenterol Clin Biol. 2008 Sep;32(6 Suppl 1):4-7 [18973842.001]
  • [Cites] Gastroenterology. 2002 Sep;123(3):745-50 [12198701.001]
  • [Cites] Diabetes. 2001 Aug;50(8):1844-50 [11473047.001]
  • [Cites] Am J Gastroenterol. 2004 Jul;99(7):1316-20 [15233671.001]
  • [Cites] Curr Diab Rep. 2008 Apr;8(2):156-63 [18445359.001]
  • [Cites] Am J Gastroenterol. 2001 Feb;96(2):519-25 [11232700.001]
  • [Cites] Eur J Radiol. 2008 May;66(2):313-20 [17646074.001]
  • [Cites] Hepatology. 1990 Nov;12(5):1106-10 [2227807.001]
  • [Cites] Gastroenterology. 1998 Apr;114(4):842-5 [9547102.001]
  • [Cites] Mod Pathol. 2007 Feb;20 Suppl 1:S40-8 [17486051.001]
  • [Cites] Hepatology. 2003 Sep;38(3):664-73 [12939593.001]
  • [Cites] Am J Clin Nutr. 2006 Jul;84(1):136-42; quiz 268-9 [16825687.001]
  • [Cites] Gut. 2008 May;57(5):649-54 [18276725.001]
  • [Cites] Dig Dis Sci. 1982 Mar;27(3):265-8 [6176409.001]
  • [Cites] World J Gastroenterol. 2008 Jun 14;14 (22):3476-83 [18567074.001]
  • [Cites] Ann Hepatol. 2009;8 Suppl 1:S4-8 [19381118.001]
  • [Cites] Gastroenterology. 2005 Mar;128(3):742-55 [15765409.001]
  • [Cites] Diabetologia. 2005 Apr;48(4):634-42 [15747110.001]
  • [Cites] Gastroenterology. 2003 Jan;124(1):71-9 [12512031.001]
  • [Cites] Gastroenterology. 2005 Jun;128(7):1898-906 [15940625.001]
  • [Cites] Am J Med. 1999 Nov;107(5):450-5 [10569299.001]
  • [Cites] Hepatology. 2007 Jun;45(6):1375-81 [17518368.001]
  • (PMID = 28839568.001).
  • [ISSN] 2041-4137
  • [Journal-full-title] Frontline gastroenterology
  • [ISO-abbreviation] Frontline Gastroenterol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  •  go-up   go-down


3. Stengel JZ, Harrison SA: Nonalcoholic Steatohepatitis: Clinical Presentation, Diagnosis, and Treatment. Gastroenterol Hepatol (N Y); 2006 Jun;2(6):440-449

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nonalcoholic Steatohepatitis: Clinical Presentation, Diagnosis, and Treatment.
  • Nonalcoholic fatty liver disease (NAFLD) is reaching epidemic proportions in our society and is the most common etiology for patients presenting with elevated liver enzymes.
  • Given the significant numbers of patients presenting with NAFLD, it is important to distinguish between simple fatty liver and nonalcoholic steatohepatitis (NASH).
  • Whereas simple fatty liver is thought to have a benign prognosis generally, NASH may progress to cirrhosis in a subset of patients.
  • Performance of liver biopsies in all NAFLD patients is not feasible but recent studies have identified several clinical factors that may predict the patients at greatest risk for NASH and advanced fibrosis, and thus biopsy procedures may be confined to the patients meeting these criteria.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Gastroenterol. 2006 Feb;101(2):368-73 [16454845.001]
  • [Cites] JAMA. 2003 Sep 24;290(12 ):1577; author reply 1578 [14506111.001]
  • [Cites] Am J Gastroenterol. 2003 Apr;98(4):926-30 [12738478.001]
  • [Cites] Gastroenterology. 2001 Jul;121(1):91-100 [11438497.001]
  • [Cites] Hepatology. 2004 Nov;40(5):1222-5 [15382153.001]
  • [Cites] Jpn J Med. 1988 May;27(2):142-9 [3047469.001]
  • [Cites] Nat Med. 2000 Sep;6(9):998-1003 [10973319.001]
  • [Cites] Hepatology. 2004 Jul;40(1):46-54 [15239085.001]
  • [Cites] Hepatology. 2004 Jun;39(6):1639-46 [15185305.001]
  • [Cites] J Clin Gastroenterol. 2004 Oct;38(9):801-4 [15365409.001]
  • [Cites] Gastroenterology. 1994 Oct;107(4):1103-9 [7523217.001]
  • [Cites] Indian J Exp Biol. 2005 Feb;43(2):177-80 [15782820.001]
  • [Cites] Gastroenterology. 2000 Jun;118(6):1117-23 [10833486.001]
  • [Cites] J Clin Endocrinol Metab. 1999 Nov;84(11):4293 [10566691.001]
  • [Cites] Gastroenterology. 2001 Jul;121(1):148-55 [11438504.001]
  • [Cites] Hepatology. 2004 Mar;39(3):770-8 [14999696.001]
  • [Cites] Hepatology. 2003 Jun;37(6):1286-92 [12774006.001]
  • [Cites] Gut. 2004 Mar;53(3):413-9 [14960526.001]
  • [Cites] Hepatology. 1999 Dec;30(6):1356-62 [10573511.001]
  • [Cites] Gastroenterology. 2002 Jul;123(1):375-8 [12105866.001]
  • [Cites] Proc Nutr Soc. 2003 Feb;62(1):201-6 [12749347.001]
  • [Cites] J Pediatr. 2000 Jun;136(6):734-8 [10839868.001]
  • [Cites] Hepatology. 2002 Oct;36(4 Pt 1):829-39 [12297830.001]
  • [Cites] Hepatology. 2002 Jun;35(6):1485-93 [12029634.001]
  • [Cites] Aliment Pharmacol Ther. 2004 Sep 15;20(6):623-8 [15352910.001]
  • [Cites] Hepatology. 1994 Dec;20(6):1442-9 [7982643.001]
  • [Cites] Am J Gastroenterol. 2002 Jun;97(6):1496-500 [12094872.001]
  • [Cites] Gastroenterology. 2002 Jul;123(1):134-40 [12105842.001]
  • [Cites] J Hepatol. 2000 Nov;33(5):716-24 [11097478.001]
  • [Cites] Aliment Pharmacol Ther. 2004 Jul 1;20(1):23-8 [15225167.001]
  • [Cites] Invest Radiol. 2000 May;35(5):319-24 [10803673.001]
  • [Cites] Am J Gastroenterol. 2004 Jan;99(1):76-81 [14687145.001]
  • [Cites] Kidney Int. 2003 Aug;64(2):459-67 [12846741.001]
  • [Cites] J Hepatol. 1997 Jul;27(1):103-7 [9252081.001]
  • [Cites] Hepatology. 2005 Jun;41(6):1313-21 [15915461.001]
  • [Cites] Hepatology. 2004 Jan;39(1):188-96 [14752837.001]
  • [Cites] Am J Gastroenterol. 2004 Dec;99(12):2365-8 [15571584.001]
  • [Cites] J Hepatol. 2003 Jan;38(1):32-8 [12480557.001]
  • [Cites] World J Gastroenterol. 2005 Jan 14;11(2):255-9 [15633226.001]
  • [Cites] Mayo Clin Proc. 1980 Jul;55(7):434-8 [7382552.001]
  • [Cites] Clin Gastroenterol Hepatol. 2004 Dec;2(12):1107-15 [15625656.001]
  • [Cites] Gut. 2005 Jan;54(1):122-7 [15591516.001]
  • [Cites] N Engl J Med. 2000 Nov 16;343(20):1467-76 [11078773.001]
  • [Cites] Am J Gastroenterol. 2001 Sep;96(9):2711-7 [11569700.001]
  • [Cites] Dig Dis Sci. 2004 Oct;49(10):1578-83 [15573908.001]
  • [Cites] Gastroenterology. 1998 Feb;114(2):311-8 [9453491.001]
  • [Cites] Trends Endocrinol Metab. 2004 Nov;15(9):425-31 [15519889.001]
  • [Cites] J Clin Endocrinol Metab. 2005 Jun;90(6):3191-6 [15769987.001]
  • [Cites] Gastroenterology. 1999 Jun;116(6):1413-9 [10348825.001]
  • [Cites] Clin Liver Dis. 2004 Nov;8(4):861-79, ix [15464659.001]
  • [Cites] Ann Intern Med. 2002 Apr 2;136(7):493-503 [11926784.001]
  • [Cites] Am J Gastroenterol. 2003 Nov;98(11):2485-90 [14638353.001]
  • [Cites] Gastroenterology. 2003 Jul;125(1):117-25 [12851877.001]
  • [Cites] J Clin Endocrinol Metab. 1999 May;84(5):1513-7 [10323371.001]
  • [Cites] Hepatology. 2004 Jun;39(6):1647-54 [15185306.001]
  • [Cites] Gastroenterology. 2005 Jul;129(1):113-21 [16012941.001]
  • [Cites] Hepatology. 2004 Dec;40(6):1387-95 [15565570.001]
  • [Cites] J Hepatol. 1991 Mar;12(2):224-9 [2051001.001]
  • [Cites] Hepatology. 2003 Oct;38(4):1008-17 [14512888.001]
  • [Cites] Immunology. 1994 Oct;83(2):262-7 [7835945.001]
  • [Cites] Hepatology. 1990 Jan;11(1):74-80 [2295475.001]
  • [Cites] Hepatology. 1992 Oct;16(4):1014-21 [1398481.001]
  • [Cites] Aliment Pharmacol Ther. 2001 Oct;15(10):1667-72 [11564008.001]
  • [Cites] Gastroenterology. 2002 Sep;123(3):745-50 [12198701.001]
  • [Cites] Gastroenterol Clin North Am. 2005 Mar;34(1):91-104 [15823441.001]
  • [Cites] Obes Surg. 2003 Jun;13(3):347-9 [12841891.001]
  • [Cites] Hepatology. 1996 Jun;23(6):1464-7 [8675165.001]
  • [Cites] Circulation. 2003 Sep 30;108(13):1546-51 [14517150.001]
  • [Cites] Hepatology. 2002 Jul;36(1):142-9 [12085358.001]
  • [Cites] Hepatology. 1990 Nov;12(5):1106-10 [2227807.001]
  • [Cites] Aliment Pharmacol Ther. 2004 Mar 1;19(5):537-44 [14987322.001]
  • [Cites] Hepatology. 2004 Oct;40(4):820-6 [15382171.001]
  • [Cites] Hepatol Res. 2001 Oct;21(2):147-158 [11551835.001]
  • [Cites] J Hepatol. 1999 Sep;31(3):421-9 [10488699.001]
  • [Cites] Pharmacotherapy. 2000 Mar;20(3):270-9 [10730683.001]
  • [Cites] Atherosclerosis. 2004 Jan;172(1):127-33 [14709366.001]
  • [Cites] Int J Obes Relat Metab Disord. 2004 Aug;28(8):1064-71 [15254487.001]
  • [Cites] Gastroenterology. 2002 Apr;122(4):931-9 [11910345.001]
  • [Cites] Am J Gastroenterol. 2001 Aug;96(8):2448-55 [11513189.001]
  • [Cites] J Appl Physiol (1985). 2003 Jun;94(6):2127-34 [12547845.001]
  • [Cites] J Womens Health (Larchmt). 2003 Mar;12 (2):115-22 [12737710.001]
  • [Cites] Gastroenterology. 1990 Nov;99(5):1408-13 [2210247.001]
  • [Cites] JAMA. 2002 Oct 9;288(14):1723-7 [12365955.001]
  • [Cites] Am J Physiol Endocrinol Metab. 2003 Oct;285(4):E906-16 [12959938.001]
  • [Cites] Am J Gastroenterol. 2005 May;100(5):1082-90 [15842582.001]
  • [Cites] Am J Gastroenterol. 2005 May;100(5):1072-81 [15842581.001]
  • [Cites] Am J Dig Dis. 1967 Feb;12(2):198-208 [6016689.001]
  • [Cites] Rom J Gastroenterol. 2003 Sep;12 (3):189-92 [14502318.001]
  • [Cites] Gastroenterology. 2005 Jun;128(7):1898-906 [15940625.001]
  • [Cites] Diabetes. 2005 Mar;54(3):603-8 [15734833.001]
  • [Cites] Hepatology. 2001 Oct;34(4 Pt 1):745-50 [11584371.001]
  • [Cites] Diabetologia. 1985 Jul;28(7):412-9 [3899825.001]
  • (PMID = 28316519.001).
  • [ISSN] 1554-7914
  • [Journal-full-title] Gastroenterology & hepatology
  • [ISO-abbreviation] Gastroenterol Hepatol (N Y)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; Nonalcoholic fatty liver disease / insulin resistance / metabolic syndrome / nonalcoholic steatohepatitis / obesity
  •  go-up   go-down


Advertisement
4. Wang C, Xu YQ: Diphenyl Dimethyl Bicarboxylate in the Treatment of Viral Hepatitis, Adjuvant or Curative? Gastroenterology Res; 2008 Dec;1(1):2-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : Diphenyl dimethyl bicarboxylate (DDB) has been used in some countries as hepatoprotectant adjuvant in the treatment of liver diseases, such as chronic viral hepatitis, chemical or drug induced hepatic damage.
  • Its early confirmed efficacy is to normalize elevated blood alanine aminotransferase (ALT) from different etiologies, however, it can rarely affect the rest hepatic enzymes.
  • Hence, for a long time, it has been only used as adjuvant of liver disease therapy.
  • It is still controversial that whether DDB can be beneficial to liver histology.
  • The normalization of ALT in hepatitis does not indicate therapeutic efficacy if without substantial liver histology improvement.
  • In recent years, more studies showed that DDB might have new therapeutical potentials in liver diseases, it may have the effect of anti-viral, anti-malignancy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27994699.001).
  • [ISSN] 1918-2805
  • [Journal-full-title] Gastroenterology research
  • [ISO-abbreviation] Gastroenterology Res
  • [Language] eng
  • [Publication-type] Review; Journal Article
  • [Publication-country] Canada
  • [Keywords] NOTNLM ; adjuvant / dimethyl diphenyl bicarboxylate / liver disease / schisandra chinensis / schisandrin B / viral hepatitis
  •  go-up   go-down


5. Havelková M, Randák T, Žlábek V, Krijt J, Kroupová H, Pulkrabová J, Svobodová Z: Biochemical Markers for Assessing Aquatic Contamination. Sensors (Basel); 2007 Nov 02;7(11):2599-2611

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The highest concentration of cytochrome P450 in fish liver was in the Vltava (0.241 nmol mg-1 protein), and the lowest was in the Orlice (0.120 nmol mg-1 protein).
  • The highest EROD activity in fish liver was in the Vltava (576.4 pmol min-1 mg-1 protein), and the lowest was in the Orlice (63.05 pmol min-1 mg-1 protein).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Toxicol Environ Health A. 1998 Mar 27;53(6):455-77 [9537282.001]
  • [Cites] Environ Pollut. 2005 Jul;136(2):231-42 [15840531.001]
  • [Cites] Chemosphere. 1997 May;34(9-10):2183-92 [9159913.001]
  • [Cites] Environ Toxicol Chem. 2001 Jan;20(1):149-59 [11351403.001]
  • [Cites] Drug Metab Dispos. 1997 May;25(5):564-72 [9152595.001]
  • [Cites] Ecotoxicol Environ Saf. 1994 Jun;28(1):35-42 [7523066.001]
  • [Cites] Environ Toxicol Chem. 2002 Sep;21(9):1864-75 [12206426.001]
  • [Cites] J Food Prot. 2007 Mar;70(3):706-15 [17388063.001]
  • [Cites] Gen Comp Endocrinol. 2003 Jun 15;132(2):223-30 [12812769.001]
  • [Cites] Sci Total Environ. 2006 Aug 31;367(2-3):715-31 [16740295.001]
  • [Cites] Comp Biochem Physiol C. 1987;86(2):233-45 [2882912.001]
  • [Cites] Chemosphere. 2007 Jan;66(3):542-52 [16860843.001]
  • [Cites] Ecotoxicol Environ Saf. 2002 Feb;51(2):145-53 [11886188.001]
  • [Cites] Chemosphere. 1998 Oct-Nov;37(9-12):2459-71 [9828349.001]
  • [Cites] Environ Toxicol Pharmacol. 2003 Feb;13(2):57-149 [21782649.001]
  • [Cites] Environ Sci Technol. 1994 Dec 1;28(13):2242-8 [22176041.001]
  • [Cites] Ecotoxicol Environ Saf. 1995 Jun;31(1):49-56 [7544264.001]
  • [Cites] Sci Total Environ. 2007 May 15;377(2-3):296-307 [17395248.001]
  • [Cites] Chemosphere. 2006 May;63(8):1342-52 [16289695.001]
  • [Cites] Environ Pollut. 2003;124(3):497-507 [12758029.001]
  • [Cites] Chemosphere. 2001 Apr;43(2):167-82 [11297396.001]
  • [Cites] Sci Total Environ. 2004 Sep 20;331(1-3):157-75 [15325147.001]
  • [Cites] J Biol Chem. 1951 Nov;193(1):265-75 [14907713.001]
  • [Cites] Environ Monit Assess. 2007 Apr;127(1-3):47-54 [16957855.001]
  • [Cites] Environ Health Perspect. 1996 Aug;104 Suppl 4:741-803 [8880001.001]
  • [Cites] Bull Environ Contam Toxicol. 2006 Feb;76(2):233-41 [16468001.001]
  • [Cites] Environ Toxicol Chem. 2005 Aug;24(8):1968-78 [16152969.001]
  • [Cites] Toxicol Appl Pharmacol. 2007 Jun 1;221(2):158-67 [17475301.001]
  • (PMID = 28903248.001).
  • [ISSN] 1424-8220
  • [Journal-full-title] Sensors (Basel, Switzerland)
  • [ISO-abbreviation] Sensors (Basel)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Keywords] NOTNLM ; EROD / Leuciscus cephalus L. / River Elbe / cytochrome P450 / persistent organic pollutants
  •  go-up   go-down


6. Koenig S, Krause P, Hosseini ASA, Dullin C, Rave-Fraenk M, Kimmina S, Entwistle AL, Hermann RM, Hess CF, Becker H, Christiansen H: Noninvasive Imaging of Liver Repopulation following Hepatocyte Transplantation. Cell Transplant; 2009 Jan;18(1):69-78

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Noninvasive Imaging of Liver Repopulation following Hepatocyte Transplantation.
  • We recently demonstrated liver irradiation under the additional stimulus of partial hepatectomy as being an effective primer in the rat liver repopulation model based on hepatocyte transplantation.
  • Livers of dipeptidylpeptidase IV (DPPIV)-deficient rats were preconditioned with irradiation.
  • Four days later, a partial hepatectomy was performed and wild-type (DPPIV<sup>+</sup>) hepatocytes were transplanted into recipient livers via the spleen.
  • Optical imaging detected Cy5.5-specific fluorescence in the liver region of the transplanted animals, increasing in intensity with time, representing extensive host liver repopulation within 16 weeks following transplantation.
  • Comparison with ex vivo immunofluorescence staining of liver sections confirmed the optical imaging results.
  • Optical imaging constitutes a potent method of assessing the longitudinal kinetics of liver repopulation in the rat transplantation model.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28841347.001).
  • [ISSN] 1555-3892
  • [Journal-full-title] Cell transplantation
  • [ISO-abbreviation] Cell Transplant
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; DPPIV / In vivo optical imaging / Irradiation / Near infrared dye Cy5.5 / Rat liver repopulation
  •  go-up   go-down


7. Brady S, Yoshizumi T, Toncheva G, Frush D: Implementation of radiochromic film dosimetry protocol for volumetric dose assessments to various organs during diagnostic CT procedures. Med Phys; 2010 Sep;37(9):4782-4792

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Dose distributions are presented for the lungs, liver, and kidneys to demonstrate the organ volume dosimetry technique.
  • Similar comparisons within the anthropomorphic phantom also indicated a consistent difference, tracking along the low and high dose regions, for the lung (28%) (SD±8%) and liver and kidneys (15%) (SD±4%).
  • Once corrected, the average film response agreed to better than 3% (SD±2%) for the CTDI scans, and for the anthropomorphic phantom scans: 3% (SD±3%) for the lungs, 5% (SD±3%) for the liver, and 4% (SD±3%) for the kidneys.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 American Association of Physicists in Medicine.
  • (PMID = 28524581.001).
  • [ISSN] 2473-4209
  • [Journal-full-title] Medical physics
  • [ISO-abbreviation] Med Phys
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; Anatomy / CT dosimetry / Computed tomography / Computer software / Dosimetry / GafChromic XRQA / Kidneys / Liver / Lungs / Medical imaging / Radiochromic film / Standards and calibration / TLD dosimetry / Thermoluminescent dosimeters / Tissues / biological tissues / calibration / computerised tomography / dosimetry / kidney / liver / lung / phantoms / thermoluminescent dosimeters / two-dimensional dosimetry
  •  go-up   go-down


8. Yang R, Tan X, Thomas AM, Shen J, Qureshi N, Morrison DC, Van Way CW 3rd: Crocetin Inhibits mRNA Expression for Tumor Necrosis Factor-α, Interleukin-1β, and Inducible Nitric Oxide Synthase in Hemorrhagic Shock. JPEN J Parenter Enteral Nutr; 2006;30(4):297-301

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Crocetin Inhibits mRNA Expression for Tumor Necrosis Factor-α, Interleukin-1β, and Inducible Nitric Oxide Synthase in Hemorrhagic Shock.
  • The hypothesis of the present study is that treatment with crocetin at the beginning of resuscitation suppresses subsequent expression of messenger ribonucleic acid (mRNA) for tumor necrosis factor (TNF-α), interleukin-1 (IL-1β) and inducible nitric oxide synthase (iNOS).
  • Liver samples were collected for reverse transcription-polymerase chain reaction (RT-PCR) analysis of mRNA (TNF-α, IL-1β, iNOS, and β-actin).
  • RESULTS: Liver mRNA expression for TNF-α, IL-1β, and iNOS was found in more animals in the shock and shock-plus-resuscitation groups than in the sham control group.
  • CONCLUSIONS: Crocetin modified the hepatic mRNA expression of cytokines and iNOS in a shock model.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28059007.001).
  • [ISSN] 0148-6071
  • [Journal-full-title] JPEN. Journal of parenteral and enteral nutrition
  • [ISO-abbreviation] JPEN J Parenter Enteral Nutr
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


9. Van Der Windt DJ, Echeverri GJ, Ijzermans JNM, Cooper DKC: The Choice of Anatomical Site for Islet Transplantation. Cell Transplant; 2008 Sep;17(9):1005-1014

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • However, other sites, such as the omentum, offer drainage of produced insulin into the portal vein for direct utilization in the liver.
  • Eventually, the liver will most likely be replaced by a site that allows long-term survival of islets from a single donor to reverse type 1 diabetes.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28863751.001).
  • [ISSN] 1555-3892
  • [Journal-full-title] Cell transplantation
  • [ISO-abbreviation] Cell Transplant
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; Immune privilege / Intraportal / Islet transplantation / Omental pouch / Subcutaneous / Xenotransplantation
  •  go-up   go-down


10. Cunningham SC, Dane AP, Spinoulas A, Alexander IE: Gene Delivery to the Juvenile Mouse Liver Using AAV2/8 Vectors. Mol Ther; 2008 Jun;16(6):1081-1088

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gene Delivery to the Juvenile Mouse Liver Using AAV2/8 Vectors.
  • : Recombinant adeno-associated viral (rAAV) vectors have shown promise for use in liver-targeted gene delivery, but their effects have not been extensively investigated in the immature liver.
  • Understanding the impact of liver growth on the efficacy of transduction is essential, because many monogenic liver diseases that are amenable to gene therapy will require treatment early in life.
  • Here we show that rAAV2/8 transduces the neonatal mouse liver with high efficiency.
  • With just one doubling in liver weight, however, there is a rapid reduction in vector genome numbers, irrespective of form, and the loss of episomal vector is almost complete by 2 weeks.
  • We also found that intraperitoneal (IP) delivery of rAAV2/8 was highly effective at all ages, and that promoter selection is the critical determinant of the intensity and pattern of transgene expression across the hepatic lobule.
  • We conclude that successful use of rAAV to treat liver disease in early childhood will require optimally efficient vector constructs and probable re-administration.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2008 The American Society of Gene Therapy. Published by Elsevier Inc. All rights reserved.
  • (PMID = 28178471.001).
  • [ISSN] 1525-0024
  • [Journal-full-title] Molecular therapy : the journal of the American Society of Gene Therapy
  • [ISO-abbreviation] Mol. Ther.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


11. Morris E, Thomas J, Forman D, Quirke P, Cottier B, Poston GJ: The need for a revised staging system of metastatic (M) colorectal cancer (CRC): Evidence from a national perspective on survival following surgically treated (HPX) liver metastases. J Clin Oncol; 2009 May 20;27(15_suppl):4099

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The need for a revised staging system of metastatic (M) colorectal cancer (CRC): Evidence from a national perspective on survival following surgically treated (HPX) liver metastases.
  • : 4099 Background: AJCC V.6 (2002) places all patients with MCRC beyond the lymph node basin of the primary tumor in a homogenous Stage 4.
  • Patients with inoperable hepatic MCRC can be made operable with curative intent with chemotherapy yet remaining in Stage 4.
  • Survival was calculated from the date of resection of each patient's primary colorectal tumor.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960750.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


12. Yue J, Yu J, Li S, Yin Y, Liu T, Zhu J, Lu J: PhaseI/II clinical trial of dose escalation using daily on-line cone beam CT guided radiotherapy combined with active breath control after transcatheter arterial chemoembolization for hepatocellular carcinoma. J Clin Oncol; 2009 May 20;27(15_suppl):e15654

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Our previous study demonstrated that lipiodol can be a reliable surrogate of direct tumor targeting in Kv- cone beam CT(CBCT) for patients with good lipiodol embolization.
  • By reducing geometric position uncertainty, as well as liver movement, the technique of ABC combined with on-line CBCT guidance can permit CTV(clinical target volume)-PTV(planning target volume) margin reduction and dose escalation.
  • The purpose of the study is to apply the new technique for clinical application and investigate the dose escalation, toxicities and response of liver tumors with the technique combined with chemoembolization(TACE).
  • METHODS: 20 HCC patients with Child-Pugh A liver function score were treated by daily on-line CBCT guided radiotherapy relying on lipiodol combined with ABC after TACE.
  • Each mean liver dose not reached 23G y, V30 ( the percentage of normal liver volume with radiation dose≥30 Gy) less than 28%.
  • None of these patients developed Grade 2 or greater liver toxicity except two patients developed Grade 2 gastrointestinal complications and one had grade 1 acute liver toxicity.The overall immediate tumor response rate was 76.3%.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962778.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


13. Chi Z, Cui C, Yuan X, Si L, Sheng X, Shen L, Guo J: Intra-arterial hepatic bio-chemotherapy for the treatment of melanoma patients with liver metastasis: A phase II clinical study. J Clin Oncol; 2009 May 20;27(15_suppl):e20014

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intra-arterial hepatic bio-chemotherapy for the treatment of melanoma patients with liver metastasis: A phase II clinical study.
  • : e20014 Background: To investigate the efficacy and safety of hepatic intra-arterial infusion of cisplatin, fotemustine combined with systemic dacarbazine for the treatment of melanoma patients with liver metastasis.
  • METHODS: From 2005.7 to 2008.7, thirty-six melanoma patients with liver metastatic were enrolled.
  • Systemic dacarbazine (250mg/m<sup>2</sup> d1-5) and intra-arterial hepatic (i.a.h.) of cisplatin (75mg/m<sup>2</sup> d6) and fotemustine (100mg/m<sup>2</sup> d7) were given repeated for 4-weeks.
  • CONCLUSIONS: Intra-arterial hepatic chemotherapy show its efficacy and may prolong PFS in melanoma patients with liver metastasis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962560.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


14. Schilling G, Schuch G, Panse JP, Sterneck M, Bokemeyer C: Activity of lenalidomide in metastatic hepatic epithelioid hemangioendothelioma (HEH): A case report. J Clin Oncol; 2009 May 20;27(15_suppl):e21527

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Activity of lenalidomide in metastatic hepatic epithelioid hemangioendothelioma (HEH): A case report.
  • : e21527 Background: HEH is a rare tumor of the liver with an unpredictable malignant potential.
  • Surgical resection or liver transplantation is recommended in locally advanced disease and has been successfully performed in selected cases with extrahepatic manifestations.
  • CASE REPORT: A 33-year old caucasian previously healthy male was admitted to hospital with newly diagnosed suspicious lesions in liver and spleen.
  • Biopsy revealed a tumor with predominant epithelioid cells, positive for CD31 and CD34 and negative for CD117, HHV8, AFP and CEA, classified as a HEH.
  • Retrospective analysis after 9 cycles demonstrated stable disease in comparison to the recent investigation, but an overall progression of 22% according to RECIST criteria in the liver was observed.
  • Due to the excellent tolerance we increased the daily dose to 30 mg (21/28) and 6 months later a slight regression in the lung and overall stable disease in the liver was observed.
  • The patient was listed for liver transplantation and after another 4 months on lenalidomide 30 mg, he was successfully transplanted recently.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963457.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Aliberti C, Benea G, Tilli M, Fiorentini G: Transarterial chemoembolization (TACE) of liver metastases (LM) from colorectal carcinoma (CRC) adopting drug eluting beads preloaded with irinotecan (DEBIRI): Results of a phase II study on 82 patients. J Clin Oncol; 2009 May 20;27(15_suppl):4092

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transarterial chemoembolization (TACE) of liver metastases (LM) from colorectal carcinoma (CRC) adopting drug eluting beads preloaded with irinotecan (DEBIRI): Results of a phase II study on 82 patients.
  • A suspension of polyvinyl-alcohol beads (DC Bead) preloaded with Irinotecan ( 81 TACE procedures with 2ml of microspheres preloaded with 100mgr of Irinotecan and 104 with 4ml loaded with 200mgr of Irinotecan) was delivered selectively into hepatic arteries.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961670.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Herrero A, Pulitano C, Dondero F, Dokmak S, Aussilhou B, Sauvanet A, Farges O, Faivre S, Belghiti J: Use of partial liver resection according to carcinologic procedures as an alternative to liver transplantation for HCC. J Clin Oncol; 2009 May 20;27(15_suppl):e15628

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Use of partial liver resection according to carcinologic procedures as an alternative to liver transplantation for HCC.
  • : e15628 Background: There are some arguments showing that anatomic resection, anterior approach and preoperative transarterial chemoembolization (TACE) with portal vein embolization (PVE) before major resection improves long term survival after partial liver resection for HCC.
  • This oncologic approach could compete with liver transplantation (LT) which remains poorly accessible in western countries and inaccessible in the greatest part of the world.The aim of this study was to evaluate in patients with good liver function.the result of partial liver resection with an intended carcinologic approach.
  • METHODS: Between 1998 and 2007, among 210 patients resected for HCC, we selected a subgroup of 36 patients with single and small HCC (< 6 cm) developed on chronic liver disease (CLD) who underwent anatomic partial resection and anterior approach and TACE and PVE in case of major resection.
  • The mean size of the tumor was 5.2 cm and 86% (n=31) had major resection.
  • Tumor recurrence occurred in 16 cases( 44%) after a mean delay of 21 months (ranging from 5 to 58 months).
  • CONCLUSIONS: Partial liver resection for small tumors in patients with good liver function according to carcinologic procedures allow an excellent overall and disease free survival which can challenge LT.
  • In the case of single HCC <6cm on chronic liver disease, this surgical approach may therefore be considered as a valuable alternative to LT within a curative intent.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962710.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Garufi C, Torsello A, Tumolo S, Mottolese M, Campanella C, Zeuli M, Lo Re G, Sperduti I, Pizzi G, Ettorre GM: POCHER (preoperative chemotherapy for hepatic resection) with cetuximab (Cmab) plus CPT-11/5-fluorouracil (5-FU)/leucovorin(FA)/oxaliplatin (L-OHP) (CPT-11-FFL) in unresectable colorectal liver metastases (CLM). J Clin Oncol; 2009 May 20;27(15_suppl):e15020

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] POCHER (preoperative chemotherapy for hepatic resection) with cetuximab (Cmab) plus CPT-11/5-fluorouracil (5-FU)/leucovorin(FA)/oxaliplatin (L-OHP) (CPT-11-FFL) in unresectable colorectal liver metastases (CLM).
  • Aim of the study was to have at least 30% liver resection rate (power of 80% for p0=10% and p1=25%).
  • Primary tumor: colon/rectum 34/9, primary tumor resected 39 pts (79%), synchronous metastases: 35 pts (81%), liver <25%/25%: 9/34 ((21/79%); median CEA/CA19-9: 55 ng/ml (1-6,600)/91.8 U/L (2.66440); unresectability: (a): 9 (21%), (b):14 (33%), (c) 1, (d): 4 (9%), (e): 15 (35%).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964412.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Karimdjee BS Sr, Cambien MB, Richard MP, Bereder J Sr, Scoazec MJ, Birnbaum MD, Mounier MN, Schmid MH, Schmid MA: Organ-specific inhibition of metastatic colon carcinoma by CXCR3 antagonism. J Clin Oncol; 2009 May 20;27(15_suppl):e14619

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : e14619 Background: Liver and lung metastases are the predominant cause of colorectal cancer (CRC) related mortality.
  • Recent research has indicated that CXCR3/chemokines interactions that orchestrate hematopoetic cell movement are implicated in the metastatic process of malignant tumors, including that of CRC cells to lymph nodes.
  • To date, however, the contribution of CXCR3 to liver and lung metastasis in CRC has not been addressed.
  • METHODS: To determine whether CXCR3 receptors regulate malignancy-related properties of CRC cells, we have used CXCR3-expressing CRC cell lines of human (HT29 cells) and murine (C26 cells) origins that enable the development of liver and lung metastases when injected into immunodeficient and immunocompetent mice, respectively, and assessed the effect of CXCR3 blockade using AMG487, a small molecular weight antagonist.
  • In vivo, systemic CXCR3 antagonism by preventive or curative treatments with AMG487 markedly inhibited metastasis of human and mouse CRC cells to the lung without affecting that to the liver.
  • Also, we measured increased levels of CXCR3 and ligands expression within lung nodules compared to liver tumors.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964128.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Alexandrova K, Griesel C, Barthold M, Heuft HG, Ott M, Winkler M, Schrem H, Manns MP, Bredehornsp T, Net M, Vidal MMI, Kafert-Kasting S, Arseniev L: Large-Scale Isolation of Human Hepatocytes for Therapeutic Application. Cell Transplant; 2005 Nov;14(10):845-853

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • During the last decade, hepatocyte transplantation has been suggested as a safe and potentially effective clinical option for the treatment of acute or decompensating chronic liver failure as well as for hereditary liver disease.
  • Currently, one of the major limiting factors for clinical application is the insufficient access to suitable liver cell preparations.
  • The mean specific yield was 3.6 × 106 total and 2.6 × 106 viable cells per gram liver tissue, respectively.
  • Specific cell yields from three infantile donor livers were considerably higher.
  • In summary, a standardized and cGMP conform method of hepatocyte isolation from nontransplantable liver organs was established, which reproducibly yields large amounts of hepatocytes suitable for therapeutic application.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28849979.001).
  • [ISSN] 1555-3892
  • [Journal-full-title] Cell transplantation
  • [ISO-abbreviation] Cell Transplant
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; Cell transplantation / GMP / Hepatocyte isolation / Steatosis
  •  go-up   go-down


20. Bensalem A, Bouzid K: Docetaxel plus capecitabine in the treatment of previous anthracycline-treated patients with metastatic breast cancer. J Clin Oncol; 2009 May 20;27(15_suppl):e12014

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The sites of metastases were liver in 14 ( 77.7%), lung in 5 (27.7%) and bone in 9 (50%).
  • The main toxicities were as follows: neutropenia grade 3 in 3 patients (16.6 %), anemia grade 2-3 in 2 patients (11.1%), fatigue in 2 patients (11.1%), hand-foot syndrome in 7 patients (38.9%), vomiting-nausea in 4 patients (22.2%), diarrhea in 2 patients (11.1%), liver toxicity in 3 patients (16.6%).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964240.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


21. Artinyan A, Castillo E, Foster B, Wagman L: Evaluation of the potential association of preoperative chemotherapy with steatohepatitis in surgical patients with hepatic colorectal metastases. J Clin Oncol; 2009 May 20;27(15_suppl):e15009

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of the potential association of preoperative chemotherapy with steatohepatitis in surgical patients with hepatic colorectal metastases.
  • : e15009 Background: The treatment of hepatic colorectal cancer metastases is increasingly multi-modal.
  • MATERIALS AND METHODS: 149 patients who had undergone liver resection or biopsy for hepatic colorectal cancer metastases were identified from an institutional database.
  • Preoperative non-contrast CT scans were reviewed for evidence of steatosis as determined by the radiographic liver/spleen (L/S) ratio.
  • In patients undergoing liver resection, there was no difference in total ICU stay, blood loss, total surgery time or total length of stay between the steatohepatitis and non-steatohepatitis groups.
  • CONCLUSIONS: Although steatohepatitis remains a potential complication of systemic chemotherapy in surgical patients with hepatic colorectal metastases, the risk and impact of chemotherapy associated steatohepatitis have not been significant in our patient population.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964364.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


22. Yopp AC, Shia J, Allen PJ, DeMatteo RP, Jarnagin WR, Fong Y, Blumgart L, D'Angelica MI: Use of CXCR4 as a prognostic marker for disease-specific survival and pattern of recurrence following resection of hepatic colorectal metastases. J Clin Oncol; 2009 May 20;27(15_suppl):11081

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Use of CXCR4 as a prognostic marker for disease-specific survival and pattern of recurrence following resection of hepatic colorectal metastases.
  • : 11081 Background: Expression of the chemokine receptors CXCR4 and CCR7 has been associated with metastases and poor prognosis in primary tumors but their relevance in colorectal liver metastases (CLM) is unclear.
  • This study examines the relationship between tumor chemokine receptor expression, pattern of recurrence and outcome after resection of hepatic metastases.
  • METHODS: Eighty patients with metastases from colon or rectal primary tumors who underwent a R<sub>0</sub> partial hepatectomy from February 2002 to April 2004 were studied prospectively.
  • Immunohistochemical staining was performed on the formalin-fixed, paraffin-embedded tissues of hepatic metastases using antibodies specific for CXCR4, CXCL12 and CCR7.
  • Positive expression of CXCR4, CXCL12 and CCR7 was seen in 49 (61%), 23 (29%) and 48 (60%) of tumor specimens, respectively.
  • CCR7 and CXCL12 expression, hepatic artery infusion pump chemotherapy, systemic chemotherapy and site of primary disease did not influence DSS or RFS.
  • Fifty-three (68%) of the patients recurred; 11 with liver only recurrences, 25 with lung only recurrences and 18 with multiple sites of recurrences.
  • CONCLUSIONS: CXCR4 expression in colorectal hepatic metastases adds prognostic information with regards to DSS, RFS and patterns of recurrence and may play role in clinical decision making regarding chemotherapy and surgical interventions.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963167.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


23. Vogl TJ, Naguib N, Zangos S, Eichler K, Gruber T: Repeated transarterial chemoperfusion and -embolization (TACE) in primary hepatic cholangiocarcinoma (CCC): Local tumor control and survival rate. J Clin Oncol; 2009 May 20;27(15_suppl):e15595

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Repeated transarterial chemoperfusion and -embolization (TACE) in primary hepatic cholangiocarcinoma (CCC): Local tumor control and survival rate.
  • : e15595 Background: To evaluate local tumor control and survival data in the palliative and symptomatic treatment of hepatic cholangiocarcinoma (CCC) using repeated transarterial chemoperfusion and -embolization (TACE) with two different chemotherapy protocols.
  • 22 patients had multiple tumors, 6 showed 1 lesion, 5 had 2 lesions and 8 presented 3 to 4 lesions.
  • Tumor response was evaluated by magnetic resonance imaging (MRI) in 3-month intervals.
  • RESULTS: Evaluation of local tumor control according to the RECIST criteria was as follows: partial response 9.8%, stable disease 43.6%, and progressive disease 46.6%.
  • The mean survival time from the date of diagnosis of liver involvement was 34.1 months (according to Kaplan-Meier), after first TACE treatment 16.7 months.
  • CONCLUSIONS: Our data indicated that repeated TACE using the protocols is well tolerated and yields respectable results in patients with unresectable liver lesions from CCC.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962884.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


24. Lencioni R, Malagari K, Vogl T, Pilleul F, Denys A, Watkinson A, Lammer J: A randomized phase II trial of a drug eluting bead in the treatment of hepatocellular carcinoma by transcatheter arterial chemoembolization. J Clin Oncol; 2009 May 20;27(15_suppl):4523

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Recently, a drug-eluting bead (DEB) has been developed to enhance drug delivery to the tumor and reduce its systemic availability.
  • METHODS: Two hundred and twelve patients (185 males and 27 females; mean age, 67 years) with Child-Pugh A or B liver cirrhosis and large and/or multinodular, unresectable HCC were randomized to receive DEB-TACE (DC Bead; Biocompatibles, UK) uploaded with doxorubicin or conventional TACE with doxorubicin, lipiodol, and gelatin sponge particles.
  • Tumor response at 6 months was the primary study endpoint.
  • An independent, blinded review of magnetic resonance imaging studies was conducted to assess tumor response according to amended RECIST criteria.
  • There was a marked reduction in serious liver toxicity in patients treated with DEB-TACE.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962723.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


25. Vigo SA, Sansano M, Marmissolle F, Mainella A, Lujan L, Price P, Antonelli M, Mohamed F, Giacomi N: Characteristics and behavior of HER-2/neu positive tumors in patients under 35 years of age with breast cancer. J Clin Oncol; 2009 May 20;27(15_suppl):e11634

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Characteristics and behavior of HER-2/neu positive tumors in patients under 35 years of age with breast cancer.
  • It is believed that tumor is more aggressive in biologic nature in this group of pts.
  • OBJECTIVE: to describe Her2/neu status, tumor behavior and prognosis in women aged 35 and under with BC.
  • METHODS: We reviewed the records of 45 women aged 35 years or less, with diagnosis of BC between 1999 and 2007.
  • RESULTS: Her2/neu overexpression showed up in 8 tumors (17.7%) and all of them were confirmed by FISH.
  • Stage at diagnosis was I 2 pts and II 6 pts.
  • 5 out of the 8 pts with Her2/neu tumors had axillary node involvement (11.1% out of the total of population), and tumor size was more than 2cm at diagnosis.
  • Postoperative radiotherapy was given to 6pts while all pts with Her2/neu positive tumors received chemotherapy with anthracyclines, taxanes and trastuzumab.
  • Disease free survival of 24 month was achieved in 5pts, 1pt died with bone, lung and liver metastases.
  • In this small group of pts lymph node involvement was frequent and tumor size was more than 2cm.
  • Progressive disease with distant metastases in bone, lung and liver was observed.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961197.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


26. Alexandre J, Ray-Coquard I, Selle F, Floquet A, Cottu P, Weber B, Falandry C, Lebrun D, Pujade-Lauraine E, GINECO-Group: Clinical presentation and sensitivity to platinum-based chemotherapy (CT) of mucinous advanced epithelial ovarian carcinoma (M-AEOC): The GINECO-Group experience. J Clin Oncol; 2009 May 20;27(15_suppl):5572

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Extra-peritoneal mets (stage IV) were more frequent in M- than in S-AEOC pts (30% versus 15%, p = 0.004), specially liver mets (44% of stage IV pts versus 23%, p = 0.06).
  • CONCLUSIONS: Compared to S-AEOC, M-AEOC is characterized by more limited peritoneal carcinomatosis but more frequent liver mets.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962610.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


27. Demetris AJ, Fontes P, Lunz JG 3rd, Specht S, Murase N, Marcos A: Wound Healing in the Biliary Tree of Liver Allografts. Cell Transplant; 2006 Jan;15(1_suppl):57-65

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Wound Healing in the Biliary Tree of Liver Allografts.
  • An increasing need for liver transplantation requires evaluation and triage of organs harvested from "extended criteria" donors.
  • These organs carry a statistical risk of dysfunction early after transplantation, but in the majority of recipients, hepatic parenchymal function recovers.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28863771.001).
  • [ISSN] 1555-3892
  • [Journal-full-title] Cell transplantation
  • [ISO-abbreviation] Cell Transplant
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; Biliary strictures / Liver transplantation / Wound healing
  •  go-up   go-down


28. Nwokediuko SC, Ibegbulam O: Quantitative Platelet Abnormalities in Patients With Hepatitis B Virus-Related Liver Disease. Gastroenterology Res; 2009 Dec;2(6):344-349

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Quantitative Platelet Abnormalities in Patients With Hepatitis B Virus-Related Liver Disease.
  • Quantitative abnormalities of platelets are known to occur in chronic liver disease.
  • The study was carried out to determine the abnormalities of platelet count in various forms of Hepatitis B virus-related liver disease.
  • METHODS: Platelet count was carried out on consecutive chronic liver disease patients seen at the gastroenterology unit of the University of Nigeria Teaching Hospital Ituku/Ozalla who tested positive for Hepatitis B surface antigen (HBsAg) from January 2007 to June 2009.
  • RESULTS: There were 142 patients with various forms of HBV-related liver disease (asymptomatic infection 29.6%, chronic hepatitis 8.4%, cirrhosis 27.5%, and hepatocellular carcinoma 34.5%).
  • There was no statistically significant difference between the mean platelet count in the patients with Hepatitis B virus (HBV) related liver disease as a whole and control subjects (p = 0.4655).
  • CONCLUSIONS: Abnormalities of platelet count occur in HBV-related liver disease.
  • Patients with liver cirrhosis tend to have lower platelet count while patients with HCC tend to have higher counts.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27990204.001).
  • [ISSN] 1918-2805
  • [Journal-full-title] Gastroenterology research
  • [ISO-abbreviation] Gastroenterology Res
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Canada
  • [Keywords] NOTNLM ; Hepatitis B virus / Liver disease / Paraneoplastic syndrome / Platelet
  •  go-up   go-down


29. Rojas Llimpe F, Di Fabio F, Ercolani G, Giampalma E, Serra C, Castellucci P, Pini S, Mutri V, Golfieri R, Pinto C, Martoni A: Presurgical comparative imaging evaluation in patients with colorectal cancer liver metastasis (PROMETEO Study). J Clin Oncol; 2009 May 20;27(15_suppl):e15010

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Presurgical comparative imaging evaluation in patients with colorectal cancer liver metastasis (PROMETEO Study).
  • : e15010 Background: The aim of the study was to define the specific diagnostic accuracy of different imaging techniques in patients (pts) with resectable colorectal cancer liver metastasis (CLMs).
  • METHODS: Consecutive pts with, potentially resectable CLMs afferent to the Multidisciplinary Liver Team of Bologna Sant'Orsola Malpighi Hospital performed, in the 3 weeks prior to liver surgery, computed tomography scan (CT), magnetic resonance diffusion-weighted (MR-DW), and liver contrast-enhanced ultrasonography (CEUS1).
  • Liver contrast-enhanced ultrasonography was also performed intra-operatively (CEUS2).
  • RESULTS: From December 2007 to December 2008, twenty-nine out of 50 pts enrolled in the PROMETEO study underwent liver resection.
  • The pt characteristics were: 18 (62%) males, 11 (38%) females; 18 (62%) synchronous metastasis, 11 (38%) metachronous metastasis; 15 (51.7%) neoadjuvant chemotherapy; 7 (24.1%) previous liver surgery; 3 (10.3%) previous loco-regional treatment.
  • Ninety-three liver lesions were resected; the median number lesions per patient was 2 (range 1- 10).
  • CONCLUSIONS: These results show that CT, CEUS1 and MR-DW have a good accuracy in the detection of liver metastasis in patients who are candidates for resection.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964437.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


30. Li H, Lu Y, Witek RP, Chang LJ, Campbell-Thompson M, Jorgensen M, Petersen B, Song S: Ex Vivo Transduction and Transplantation of Bone Marrow Cells for Liver Gene Delivery of α1-Antitrypsin. Mol Ther; 2010 Aug;18(8):1553-1558

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ex Vivo Transduction and Transplantation of Bone Marrow Cells for Liver Gene Delivery of α1-Antitrypsin.
  • We have previously shown that liver progenitor (oval) cells can be used as a platform for liver gene delivery of human α1-antitrypsin (hAAT).
  • In the present study, we tested the feasibility of bone marrow (BM) cell-based liver gene delivery of hAAT.
  • Transplantation studies showed that transplanted BM cells homed into liver, differentiated into hepatocytes and expressed hAAT in the liver.
  • These results demonstrated that rAAV vector-mediated BM cell-based liver gene therapy is feasible for the treatment of AAT deficiency and implies a novel therapy for the treatment of liver diseases.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 The American Society of Gene & Cell Therapy. Published by Elsevier Inc. All rights reserved.
  • (PMID = 28178512.001).
  • [ISSN] 1525-0024
  • [Journal-full-title] Molecular therapy : the journal of the American Society of Gene Therapy
  • [ISO-abbreviation] Mol. Ther.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


31. Wicherts DA, de Haas RJ, Sebagh M, Ciacio O, Lévi F, Paule B, Azoulay D, Bismuth H, Castaing D, Adam R: Liver regenerative nodular hyperplasia consecutive to preoperative chemotherapy: Impact on outcome of liver surgery for colorectal metastases. J Clin Oncol; 2009 May 20;27(15_suppl):4097

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Liver regenerative nodular hyperplasia consecutive to preoperative chemotherapy: Impact on outcome of liver surgery for colorectal metastases.
  • : 4097 Background: Regenerative nodular hyperplasia (RNH) represents the worst evolutive stage of vascular lesions induced by prolonged chemotherapy on the liver.
  • Its incidence and impact on the outcome of resection for colorectal liver metastases (CLM) are however unknown.
  • Detailed histopathologic analysis of the nontumoral liver was performed at first and repeat hepatectomies according to a standard format.
  • The presence of RNH was associated with increased postoperative hepatic morbidity (23% vs 11%) (P=0.05).
  • CONCLUSIONS: Patients with CLM that receive prolonged courses of preoperative oxaliplatin have an increased risk of RNH and associated postoperative hepatic morbidity.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960752.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


32. Vaklavas C, Tsimberidou AM, Moulder S, Ng C, Naing A, Daring S, Bedikian A, Uehara C, Kurzrock R: A phase I study dose escalation clinical study of hepatic intraarterial cisplatin, combination systemic intravenous liposomal doxorubicin in patients advanced cancer dominant liver involvement. J Clin Oncol; 2009 May 20;27(15_suppl):e13512

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase I study dose escalation clinical study of hepatic intraarterial cisplatin, combination systemic intravenous liposomal doxorubicin in patients advanced cancer dominant liver involvement.
  • : e13512 Background: Patients with liver metastases treated on phase I clinical trials have a median survival of 7.5 months (range, 6.0-9.5).
  • We conducted a phase I study of hepatic arterial infusion (HAI) and intravenous (IV) chemotherapy in patients with advanced cancer and dominant liver involvement.
  • Treatment resulted in a partial response (PR)(n=4) or stable disease (SD)(n=6) by RECIST in 10 (48%) patients and lasted for ≥4 months (tumor reduction by 5% to 44%).
  • Four (19%) patients achieved a PR (tumor reduction by 38%, 42%, 44% and 51%, for 4, 4, 6, and 4 months, respectively).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961306.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


33. Deurholt T, Ten Bloemendaal L, Chhatta AA, Van Wijk ACWA, Weijer K, Seppen J, Elferink RPJO, Chamuleau RAFM, Hoekstra R: In Vitro Functionality of Human Fetal Liver Cells and Clonal Derivatives under Proliferative Conditions. Cell Transplant; 2006 Sep/Oct;15(8-9):811-822

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] In Vitro Functionality of Human Fetal Liver Cells and Clonal Derivatives under Proliferative Conditions.
  • In contrast, human fetal liver cells (HFLC) can be easily expanded in vitro.
  • In this study we evaluated the hepatic function of HFLCs under proliferative conditions, to determine whether HFLCs can replace mature hepatocytes for in vitro applications.
  • HFLCs were isolated from fetal livers of 16 weeks gestation.
  • Hepatic functions of HFLCs were determined in primary culture and after expansion in vitro.
  • Clonal derivatives were selected and tested for hepatic functionality.
  • No differences were observed between primary HFLCs and mature human hepatocytes in albumin production and mRNA levels of various liver-specific genes.
  • Expanding HFLCs decreased hepatic functions and increased cell stretching.
  • Although their hepatic functions were higher than in passaged HFLCs, functionality was at least 20 times lower compared to mature human hepatocytes.
  • HFLCs cannot replace mature human hepatocytes in in vitro applications requiring extensive in vitro expansion, because this is associated with decreased hepatic functionality.
  • In addition, defining conditions that support hepatic differentiation is necessary to obtain HFLC cultures suitable for in vitro hepatic applications.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28876098.001).
  • [ISSN] 1555-3892
  • [Journal-full-title] Cell transplantation
  • [ISO-abbreviation] Cell Transplant
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; Fetal / Hepatocyte / In vitro / Liver function / Proliferation
  •  go-up   go-down


34. Saunders J, Brian A, Wright M, Stroud M: Malnutrition and nutrition support in patients with liver disease. Frontline Gastroenterol; 2010 Jul;1(2):105-111

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malnutrition and nutrition support in patients with liver disease.
  • Liver disease, especially alcohol related, is increasingly common and is often accompanied by malnutrition as a result of reduced intake, absorption, processing and storage of nutrients.
  • Malnutrition in all forms of liver disease is associated with higher rates of mortality and morbidity but it is often under recognised and under treated despite the fact that appropriate treatment can improve outcomes.
  • In this review, the causes, consequences and assessment of nutritional status in patients with liver disease are examined, and an approach to best treatment is proposed.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] JPEN J Parenter Enteral Nutr. 1993 Mar-Apr;17(2):119-24 [8455312.001]
  • [Cites] Gastroenterology. 1991 Mar;100(3):738-44 [1993495.001]
  • [Cites] Hepatology. 1983 Jul-Aug;3(4):475-80 [6345330.001]
  • [Cites] Clin Nutr. 2006 Apr;25(2):285-94 [16707194.001]
  • [Cites] Dig Dis Sci. 1997 Mar;42(3):536-41 [9073135.001]
  • [Cites] Clin Nutr. 2009 Aug;28(4):436-44 [19520466.001]
  • [Cites] Nutrition. 2005 Feb;21(2):113-7 [15723736.001]
  • [Cites] Clin Gastroenterol Hepatol. 2005 Jul;3(7):705-13 [16206505.001]
  • [Cites] Scand J Gastroenterol. 2002 Jul;37(7):807-11 [12190094.001]
  • [Cites] Gastroenterology. 1992 Jan;102(1):200-5 [1727754.001]
  • [Cites] Nutrition. 2001 Jun;17(6):445-50 [11399401.001]
  • [Cites] Am J Clin Nutr. 1999 Jun;69(6):1194-201 [10357739.001]
  • [Cites] Transpl Int. 1997;10(5):369-74 [9287402.001]
  • [Cites] Clin Nutr. 1997 Apr;16(2):43-55 [16844569.001]
  • [Cites] Eur J Clin Nutr. 1989 Sep;43(9):615-21 [2691239.001]
  • [Cites] BMJ. 1989 Nov 11;299(6709):1202-3 [2513050.001]
  • [Cites] Transplantation. 2000 Apr 15;69(7):1364-9 [10798755.001]
  • [Cites] Hepatology. 2009 Jun;49(6):2087-107 [19475696.001]
  • [Cites] Hepatology. 2000 Dec;32(6):1208-15 [11093726.001]
  • [Cites] J Gastroenterol Hepatol. 2008 Jul;23(7 Pt 2):e43-8 [17683494.001]
  • [Cites] Hepatology. 1996 May;23(5):1041-6 [8621131.001]
  • [Cites] J Hepatol. 2004 Feb;40(2):228-33 [14739092.001]
  • [Cites] J Hepatol. 1994 Dec;21(6):940-6 [7699257.001]
  • [Cites] Proc Nutr Soc. 2007 Aug;66(3):378-83 [17637090.001]
  • [Cites] J Gastroenterol Hepatol. 2008 Apr;23(4):606-10 [18005013.001]
  • [Cites] J Gastroenterol. 2006 May;41(5):476-82 [16799890.001]
  • [Cites] Hum Nutr Clin Nutr. 1985;39 Suppl 1:5-41 [4044297.001]
  • [Cites] J Immunol. 2003 Nov 1;171(9):4837-43 [14568963.001]
  • [Cites] Am J Clin Nutr. 2007 May;85(5):1257-66 [17490961.001]
  • [Cites] J Nutr. 1994 Jun;124(6):906-10 [7515956.001]
  • [Cites] Clin Nutr. 1989 Dec;8(6):329-36 [16837309.001]
  • [Cites] Cochrane Database Syst Rev. 2003;(2):CD001939 [12804416.001]
  • [Cites] Gastroenterology. 2003 Jun;124(7):1792-801 [12806613.001]
  • [Cites] Hepatology. 2006 Oct;44(4):823-35 [17006918.001]
  • [Cites] Liver Transpl. 2000 Sep;6(5):575-81 [10980056.001]
  • [Cites] J Hepatol. 2004 Jul;41(1):38-43 [15246205.001]
  • [Cites] Lancet. 1994 Sep 24;344(8926):837-40 [7916398.001]
  • [Cites] Gastroenterology. 1990 Mar;98(3):715-20 [2105256.001]
  • [Cites] Br J Nutr. 1995 Oct;74(4):557-67 [7577893.001]
  • [Cites] J Hepatol. 1994 Sep;21(3):317-25 [7836699.001]
  • [Cites] Transplantation. 2001 Aug 27;72(4):666-70 [11544428.001]
  • [Cites] Liver Int. 2007 Nov;27(9):1194-201 [17919230.001]
  • [Cites] Liver. 1985 Oct;5(5):282-9 [4079669.001]
  • (PMID = 28839557.001).
  • [ISSN] 2041-4137
  • [Journal-full-title] Frontline gastroenterology
  • [ISO-abbreviation] Frontline Gastroenterol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  •  go-up   go-down


35. Tsuruga Y, Kiyono T, Matsushita M, Takahashi T, Kasai H, Todo S: Establishment of Immortalized Human Hepatocytes by Introduction of HPV16 E6/E7 and hTERT as Cell Sources for Liver Cell-Based Therapy. Cell Transplant; 2008 Sep;17(9):1083-1094
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Establishment of Immortalized Human Hepatocytes by Introduction of HPV16 E6/E7 and hTERT as Cell Sources for Liver Cell-Based Therapy.
  • For future cell-based therapies for liver diseases, the shortage of cell sources must be resolved.
  • Albumin synthesis and expression of liver-enriched genes were confirmed, but gradually decreased as passages progressed.
  • Subcutaneous injection of these cells into severe combined immunodeficiency (SCID) mice did not induce tumor development.
  • Intrasplenic transplantation of dedifferentiated HHE6E7T-1 cells over 200 PDs significantly improved the survival of acetaminophen-induced acute liver failure SCID mice.
  • However, the results of intrasplenic transplantation to SCID mice with acetaminophen-induced acute liver failure showed the possibility of HHE6E7T-1 serving as a cell source for hepatocyte transplantation.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28863749.001).
  • [ISSN] 1555-3892
  • [Journal-full-title] Cell transplantation
  • [ISO-abbreviation] Cell Transplant
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; Acetaminophen-induced acute liver failure / Chromosomal instability / Dedifferentiation / Hepatocyte transplantation / Tumorigenicity
  •  go-up   go-down


36. Quesson B, Merle M, Köhler MO, Mougenot C, Roujol S, de Senneville BD, Moonen CT: A method for MRI guidance of intercostal high intensity focused ultrasound ablation in the liver. Med Phys; 2010 Jun;37(6Part1):2533-2540

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A method for MRI guidance of intercostal high intensity focused ultrasound ablation in the liver.
  • PURPOSE: High intensity focused ultrasound (HIFU) is a promising method for the noninvasive treatment of liver tumors.
  • The method was validatedex vivo and in vivo in pig liver during breathing under multislice real-time MR thermometry, using the proton resonance frequency shift method.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 American Association of Physicists in Medicine.
  • (PMID = 28512934.001).
  • [ISSN] 2473-4209
  • [Journal-full-title] Medical physics
  • [ISO-abbreviation] Med Phys
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; Acoustic transducers / Biothermics and thermal processes in biology / HIFU / Liver / MR thermometry / Magnetic resonance / Magnetic resonance imaging / Medical imaging / Medical magnetic resonance imaging / Segmentation / Tissue ablation / Tissues / Transducers / Ultrasonic transducers / Ultrasonography / biomedical MRI / biothermics / bone / image segmentation / liver / medical image processing / rib / skin / tumours / ultrasonic therapy
  •  go-up   go-down


37. Adam R, Wicherts DA, de Haas RJ, Lévi F, Paule B, Azoulay D, Castaing D: Postoperative liver function recovery after hepatic resection for colorectal metastases previously treated with bevacizumab. J Clin Oncol; 2009 May 20;27(15_suppl):4093

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Postoperative liver function recovery after hepatic resection for colorectal metastases previously treated with bevacizumab.
  • : 4093 Background: The influence of bevacizumab on postoperative morbidity in patients with colorectal liver metastases (CLM) submitted to hepatectomy has been evaluated.
  • However, in spite of a potential inhibition of liver regeneration, its impact on postoperative liver function recovery remains unknown.
  • Postoperative evolution of liver function variables was compared with that of 70 bevacizumab-naïve patients.
  • Baseline liver function tests as well as postoperative liver function recovery were similar between patients treated with or without bevacizumab (Table).
  • CONCLUSIONS: Preoperative bevacizumab treatment has no impact on short-term liver function recovery after hepatic resection for CLM and has no deleterious effect on the incidence of postoperative morbidity.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961669.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


38. Benedict SH, Bova FJ, Clark B, Goetsch SJ, Hinson WH, Leavitt DD, Schlesinger DJ, Yenice KM: The role of medical physicists in developing stereotactic radiosurgery. Med Phys; 2008 Sep;35(9):4262-4277

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A major theme of the article is the expanding role of the medical physicist from that of advisor to the neurosurgeon to the current role as a primary driver of new technology that has already led to an adaptation of cranial SRS to other sites in the body, including, spine, liver, and lung.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2008 The Authors. Published by American Association of Physicists in Medicine and John Wiley & Sons Ltd.
  • (PMID = 28525045.001).
  • [ISSN] 2473-4209
  • [Journal-full-title] Medical physics
  • [ISO-abbreviation] Med Phys
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; Collimators / Dosimetry / Dosimetry/exposure assessment / Linear accelerators / Medical imaging / Medical physicists / Physicists / Protons / Radiation therapy / Radiation treatment / Radiosurgery / Stereotactic radiosurgery / dosimetry / liver / lung / neurophysiology / radiation therapy / stereotactic body radiotherapy / stereotactic radiosurgery / stereotactic radiotherapy / surgery
  •  go-up   go-down


39. Osako T, Nishimura R, Okumura Y, Hayashi M: Current status of treatment of local recurrence and distant metastasis of triple negative breast cancer in Japanese population. J Clin Oncol; 2009 May 20;27(15_suppl):e11548

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Forty two patients had already been dead and common causes of death were lung metastases (19 patients), liver metastases (11 patients), and brain metastases (8 patients).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964664.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


40. Aprile G, Miscoria M, Baldin P, Casetta A, Pandolfi M, Di Loreto C, Pizzolitto S, Pizzolitto S, Foltran L, Fasola G, Puglisi F: Chemotherapy-induced thymidine phosphorylase modulation in colorectal cancer. J Clin Oncol; 2009 May 20;27(15_suppl):e15050

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Sites of biopsied metastases were liver (n=41), lung (n=10), and peritoneum (n=6).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964542.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


41. Gupta S, Parsa V, Heilbrun L, Smith D, Dickow B, Heath E, Vaishampayan U: Safety and efficacy analysis of sunitinib (S), bevacizumab (B), and M-Tor inhibitors in metastatic renal cell cancer (mRCC) patients (pts) with renal insufficiency (RI). J Clin Oncol; 2009 May 20;27(15_suppl):5108

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : 5108 Background: S, T (temsirolimus) and E (everolimus) are primarily metabolized in the liver, while the metabolism of B is unclear.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964365.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


42. Djellali L, Larbaoui B, Boukerche A, Ghazi S, Chaiba I, Meziane N, Yekrou D, Youcef DF: Preoperative concomitant chemoradiotherapy with oxaliplatin and 5-fluorouracil in locally advanced rectal carcinoma. J Clin Oncol; 2009 May 20;27(15_suppl):e15108

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The primary endpoint of this phase II trial was pathologic tumor response.
  • Secondary endpoint was sphincter preservation and toxicity Methods: Inclusion criteria: rectal adenocarcinoma <12 cms from anal verge, clinical stage T3-4, adequate renal, hematological and liver function.
  • Tumor location (from anal verge): < 6 cm in 10pts, >6 cm in 5pts.
  • Tumor down-staging was observed in 10pts (66.6%), including 5pts with complete pathological response (33.3%).
  • Main adverse effects (NCI-CTC): diarrhea G3-4: 14.2%, sensitive peripheral neurotoxicity G1: 26.6%, nausea/vomiting G3-4: 11%, Anemia G3-4: 7.1%, neutropenia G3-4: 14.2% Conclusions: Preliminary results show that preoperative concomitant chemoradiotherapy with oxaliplatin and 5FU-folinic acid is an effective regimen with an acceptable safety profile for locally advanced rectal cancer, leading to a high probability of tumor downstaging.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964340.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


43. Toumpanakis C, Quigley A, Srirajaskanthan R, Marelli L, Singhrao T, Meyer T, Buscombe J, Caplin ME: 90-Yttrium-DOTA-octreotate for the treatment of advanced neuroendocrine tumors. J Clin Oncol; 2009 May 20;27(15_suppl):4594

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] 90-Yttrium-DOTA-octreotate for the treatment of advanced neuroendocrine tumors.
  • : 4594 Background: The expression of somatostatin receptors (SSTR) on Neuroendocrine Tumors (NETs) has led not only to tumour visualization utilizing SSTR scintigraphy, but also to the development of receptor-targeted radionuclide therapy.
  • Isotopes such as 111-Indium, 90-Yttrium and 177-Lutetium are linked to somatostatin analogues and then internalized by tumour cells.
  • In all patients, the tumours had shown good uptake either in the OctreoScan or in the Ga-68 octreotate PET scan.
  • 29/89 patients included a cycle of intra-arterial therapy with mean dose/cycle 2090 MBq for large volume liver disease.
  • RESULTS: In all patients the post treatment scintigraphy demonstrated good uptake and localization by the tumors.
  • 31/89 (35%) had continued tumor progression.
  • CONCLUSIONS: 90Y-DOTA-octreotate is a well-tolerated and safe treatment for patients with progressive neuroendocrine tumors.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963114.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


44. Malempati S, Weigel B, Ingle AM, Ahern CH, Carroll JM, Roberts CT Jr, Fox FE, Voss S, Adamson PC, Blaney SM: A phase I trial and pharmacokinetic study of IMC-A12 in pediatric patients with relapsed/refractory solid tumors: A Children's Oncology Group Phase I Consortium study. J Clin Oncol; 2009 May 20;27(15_suppl):10013

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase I trial and pharmacokinetic study of IMC-A12 in pediatric patients with relapsed/refractory solid tumors: A Children's Oncology Group Phase I Consortium study.
  • : 10013 Background: IMC-A12, a fully human IgG1 monoclonal antibody to the Insulin-Like Growth Factor-I Receptor (IGF-IR), is active preclinically in a variety of pediatric solid tumors.
  • We performed a phase I trial to determine the toxicities, maximum tolerated dose (MTD), pharmacokinetics (PK), and pharmacodynamics (PD) of IMC-A12 in children with refractory solid tumors.
  • Grade 2 or higher non-DLTs possibly attributable to IMC-A12 observed in the first course include anemia (n=4), leukopenia (n=1), lymphopenia (n=2), neutropenia (n=2), opportunistic infection (n=1), ↑liver transaminases (n=2), and hyperglycemia (n=1).
  • CONCLUSIONS: In order to exceed target trough concentrations associated with optimal anti-tumor activity in pre-clinical models, 9 mg/kg IV weekly is the recommended Phase II IMC-A12 dose in children.
  • A phase II protocol for children with refractory solid tumors will be performed.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962525.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


45. De Castro J, Cejas P, Belda-Iniesta C, Ramirez-Merino N, Barriuso J, Hernandez-Agudo E, Feliu J, Moreno-Garcia V, Martinez-Marin V, Gonzalez-Baron M: Is hepcidin involved in anemia of advanced non-small cell lung carcinoma (NSCLC) patients treated with platin-based chemotherapy? An exploratory study. J Clin Oncol; 2009 May 20;27(15_suppl):e19086

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Hepcidin, a liver-produced peptide, acts to cause a block on cellular iron export by internalisation and degradation of ferroportin.This results in iron sequestration and interrupts iron delivery to erythroid precursor cells thus causing anemia.
  • Only 10% were anemic at the diagnosis but 70% developped anemia during the treatment.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962188.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


46. Harrop R, Shingler WH, Goonewardena M, de Belin J, Kelleher M, Drury N, Treasure P, Naylor S: Analysis of immunological and clinical data resulting from four phase I and II trials of MVA-5T4 in colorectal cancer patients. J Clin Oncol; 2009 May 20;27(15_suppl):3058

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : 3058 Background: The attenuated vaccinia virus MVA has been engineered to deliver the tumor antigen 5T4 (MVA-5T4; TroVax).
  • 5T4 is a surface glycoprotein expressed by most solid tumors.
  • METHODS: Patients with histologically proven CRC were recruited to 4 independent trials in which 3 to 6 vaccinations of MVA-5T4 were scheduled to be administered either as a monotherapy, as adjuvant/neoadjuvant to surgery for respectable liver metastases or alongside treatment with FOLFIRI or FOLFOX.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961994.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


47. Hertz P, Seruga B, Le LW, Tannock IF: Global drug development in cancer: A cross-sectional study of clinical trial registries. J Clin Oncol; 2009 May 20;27(15_suppl):2520

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cancer sites that are major killers globally, and especially in the LDW (e.g., stomach, liver, and esophageal cancer) should receive priority for clinical research.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961846.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


48. Jansen M, Vernaz-Gris M, DesJardins C, Wong N, Campone M, Cortes J, Wanders J, Shuster D, Fuseau E: Population pharmacokinetics (PPK) of eribulin mesylate in patients with locally advanced or metastatic breast cancer (MBC). J Clin Oncol; 2009 May 20;27(15_suppl):2524

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Appreciable interpatient PK variability exists, a minor fraction of which was explained by measures of liver and renal function.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961843.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


49. Perez-Staub N, Chibaudel B, Paye F, Taieb J, Gayet B, Bourges O, André T, Tournigand C, Louvet C, de Gramont A: Survival after surgery in patients with initially resectable metastasis receiving adjuvant/neoadjuvant FOLFOX therapy and in patients who had surgery after FOLFOX therapy. J Clin Oncol; 2009 May 20;27(15_suppl):4118

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Patients' baseline characteristics were (MIROX/OPTIMOX %): median age 56/62 yrs, PS 0 50/73, metachronous metastasis 41/21, ≥ 2 met sites 11/18, liver met 78/88, lung met 11/19, other met 17/10, two-stage surgery 9/10, second surgery after relapse 39/22, R0 resection 91/ 85.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961218.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


50. Gamelin E, Mineur L, Chevelle C, Cailleux P, Martin L, Bastit L, Roullet B, Hasbini A, Savary J, Cellier P: Neoadjuvant radiotherapy ± tegafur-uracil plus leucovorin in rectal adenocarcinoma: Final results of a French multicenter phase III study. J Clin Oncol; 2009 May 20;27(15_suppl):4104

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • 172 pts underwent surgery (97.2%), 5 pts were not resected (4 liver and 1 lung metastases plus 1 CVA).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961187.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


51. Besse-Hammer T, Villanueva C, Campone M, Machiels J, Awada A, Magherini E, Dubin F, Semiond D, Pivot XB: A dose-escalating study of XRP6258 in combination with capecitabine, in patients (pts) with metastatic breast cancer (MBC) progressing after anthracycline and taxane therapy: Preliminary results. J Clin Oncol; 2009 May 20;27(15_suppl):1053

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Data for the first 25 pts, are available so far: median age 52 [34-74], ECOG-PS 0/1: 15/10, in first or second line chemotherapy, median of 3 (1-7) organs involved (mainly: bone, liver, lymph nodes).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961150.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


52. Rugo HS, Campone M, Amadori D, Wardley A, Villa E, Conte PF, Mudenda B, McHenry B, Pivot X: Randomized phase II study of weekly versus every-3-week ixabepilone plus bevacizumab (ixa/bev) versus paclitaxel plus bev (pac/bev) as first-line therapy for metastatic breast cancer (MBC). J Clin Oncol; 2009 May 20;27(15_suppl):1029

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Ixa/bev has greater preclinical activity than pac/bev in human tumor models.
  • Baseline characteristics were balanced between arms except for liver metastasis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961032.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


53. Neumann UP, Fotopoulou C, Neuhaus P, Sehouli J: Clinical outcome of resection of liver metastasis in patients with ovarian cancer. J Clin Oncol; 2009 May 20;27(15_suppl):e16545

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical outcome of resection of liver metastasis in patients with ovarian cancer.
  • : e16545 Background: Hepatic resection has become the standard treatment for resectable colorectal liver metastases.
  • However, in patients with ovarian cancer resectable liver metastases are rare and the issue is discussed controversially due to the lack of relevant published data.
  • The aim of this retrospective study was to evaluate the efficacy of hepatic resections in patients with ovarian cancer.
  • METHODS: Between 1991 and 2006 a total of 73 women with liver metastases underwent surgery for ovarian cancer.
  • In 40 patients a liver resection was performed.
  • RESULTS: Residual tumor after surgery was by far the strongest predictor for outcome.
  • Median survival in patients with no residual tumor was 65 months, < 0.5 cm 29 months, 1cm 6 months.
  • This data clearly show that macroscopically complete surgical cytoreductive therapy improves long-term survival in patients with ovarian cancer and liver metastases.
  • Therefore, liver resection should be always discussed if complete resection is achievable and should be part of the multimodal strategy in advanced ovarian cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960822.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


54. Gyergyay F, Nagyványi K, Bodrogi I: Decreased toxicity schedule of suitinib in renal cell cancer: 2 weeks on/1 week off. J Clin Oncol; 2009 May 20;27(15_suppl):e16113

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Of 36 pts, median age 59.5 yrs (range 42-83), M/F (26:10), ECOG: 0 (21); 1 (9); 2 (6); prior nephrectomy (35),prior radiation therapy (28), prior cytokine therapy: IFNα (25), IL-2+IFNα (9) none (2); pts with 1 metastatic organ (24); 2 metastatic sites (7); ≥ 3 sites (5); Sites of metastases: Lung (27), Bone (11), Liver (3); MSCC risk factors: 0 (20), 1-2 (14); ≥3 (2).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963329.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


55. Ueno M, Ohkawa S, Sakamoto Y, Miyakawa K, Miyagi Y: The analysis of EGFR expression and EGFR mutations in advanced pancreatic cancer. J Clin Oncol; 2009 May 20;27(15_suppl):e15629

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The tissues were obtaind from liver; 12, pancreas; 19.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962711.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


56. Okamoto I, Kaneda H, Satoh T, Okamoto W, Terashima M, Arao T, Nishio K, Nakagawa K, Konishi K, Kaiser R: Phase I clinical and biomarker study of BIBF 1120, an oral multitarget tyrosine kinase inhibitor, in patients with advanced solid tumors (ST): Impact of CD133- and CD117-positive cells on a biomarker of an antiangiogenic inhibitor. J Clin Oncol; 2009 May 20;27(15_suppl):3572

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I clinical and biomarker study of BIBF 1120, an oral multitarget tyrosine kinase inhibitor, in patients with advanced solid tumors (ST): Impact of CD133- and CD117-positive cells on a biomarker of an antiangiogenic inhibitor.
  • METHODS: BIBF 1120 (150-250 mg) was administered orally twice-daily (bid) to heavily pre-treated solid tumor (ST) patients to determine safety, tolerability, maximum tolerated dose (MTD) and pharmacokinetics (PK).
  • Dose-limiting toxicities (DLTs) of reversible Grade 3/4 elevated liver enzymes occurred in three of 12 patients at 200 mg bid and three of six patients at 250 mg bid; 200 mg bid was declared as the MTD.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961723.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


57. Li H, Gu ZK, Li XS, Hou CM, Tang PH, Mao N: Functional and Phenotypic Alteration of Intrasplenic Lymphocytes Affected by Mesenchymal Stem Cells in a Murine Allosplenocyte Transfusion Model. Cell Transplant; 2007 Jan;16(1):85-95

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In vivo eGFP tracing with polymerase chain reaction analysis revealed that grafted MSCs could migrate and settle into the lungs, spleen, liver, intestine, and skin shortly after administration.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28880677.001).
  • [ISSN] 1555-3892
  • [Journal-full-title] Cell transplantation
  • [ISO-abbreviation] Cell Transplant
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; Immunomodulation / In vivo / Lymphocyte subsets / Mesenchymal stem cells / Murine model
  •  go-up   go-down


58. Jones GL, Juszczak MT, Hughes SJ, Kooner P, Powis SH, Press M: Time Course and Quantification of Pancreatic Islet Revasculariztion following Intraportal Transplantation. Cell Transplant; 2007 May;16(5):505-516

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Syngeneic islets were transplanted selectively into the two right posterior lobes of the liver of adult Lewis rats.
  • Sections of the livers were dual stained for insulin and Bandeiraea simplicifolia and analyzed for islet morphology, area, and vascular density from day 0 to day 14 posttransplant and compared to native islets.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28866940.001).
  • [ISSN] 1555-3892
  • [Journal-full-title] Cell transplantation
  • [ISO-abbreviation] Cell Transplant
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; Endothelium / Islet transplantation / Quantification / Vascular density
  •  go-up   go-down


59. Chaturvedi P, Machacha CNE: Efficacy of Raphanus sativus in the treatment of paracetamol-induced hepatotoxicity in albino rats. Br J Biomed Sci; 2007 Jan;64(3):105-108

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In the present study, the efficacy of a methanol extract of Raphanus sativus root (RSME) is tested in albino rats that developed hepatic damage due to administration of paracetamol (100 mg/kg body weight) for 30 days.
  • RSME reduced lipid peroxidation induced by paracetamol and brought the levels of SGOT and SGPT to normal, indicating liver recovery.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28705144.001).
  • [ISSN] 0967-4845
  • [Journal-full-title] British journal of biomedical science
  • [ISO-abbreviation] Br. J. Biomed. Sci.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Keywords] NOTNLM ; Catalase / Glutathione / Lipid peroxidation / Raphanus sativus / Thiobarbituric acid reactive substance
  •  go-up   go-down


60. Pérez-López FR, Pérez-Roncero G, López-Baena MT: Vitamin D and adolescent health. Adolesc Health Med Ther; 2010;1:1-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • High-dose calcifediol depots are an alternative for guaranteeing treatment adherence and in patients with liver disease.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Pediatrics. 2008 Nov;122(5):1142-52 [18977996.001]
  • [Cites] J Clin Endocrinol Metab. 1999 Dec;84(12):4702-12 [10599739.001]
  • [Cites] J Am Diet Assoc. 2004 Jun;104(6):980-3 [15175600.001]
  • [Cites] N Engl J Med. 2007 Jul 19;357(3):266-81 [17634462.001]
  • [Cites] PLoS Genet. 2009 Feb;5(2):e1000369 [19197344.001]
  • [Cites] J Clin Endocrinol Metab. 2009 Sep;94(9):3200-6 [19549742.001]
  • [Cites] Med Hypotheses. 2008;70(4):750-9 [17920208.001]
  • [Cites] Can J Public Health. 2005 Nov-Dec;96(6):443-9 [16350869.001]
  • [Cites] Pediatrics. 2009 Sep;124(3):e371-9 [19661053.001]
  • [Cites] Endocrinol Metab Clin North Am. 2005 Sep;34(3):537-53, vii [16085158.001]
  • [Cites] Prog Biophys Mol Biol. 2006 Sep;92(1):33-8 [16618499.001]
  • [Cites] Maturitas. 2008 Feb 20;59(2):101-13 [18289805.001]
  • [Cites] Am J Clin Nutr. 2002 Dec;76(6):1446-53 [12450915.001]
  • [Cites] Arch Dis Child. 2005 Apr;90(4):373-8 [15781927.001]
  • [Cites] Ann Nutr Metab. 2009;54(1):15-21 [19194104.001]
  • [Cites] J Nutr. 2005 Feb;135(2):279-82 [15671226.001]
  • [Cites] Arch Intern Med. 2009 Mar 23;169(6):626-32 [19307527.001]
  • [Cites] Metabolism. 2008 Feb;57(2):183-91 [18191047.001]
  • [Cites] Am J Clin Nutr. 1995 Mar;61(3 Suppl):638S-645S [7879731.001]
  • [Cites] Bone. 2003 Aug;33(2):242-7 [14499358.001]
  • [Cites] Arch Phys Med Rehabil. 1999 Jan;80(1):54-8 [9915372.001]
  • [Cites] Mol Genet Metab. 2009 Mar;96(3):113-20 [19147383.001]
  • [Cites] Endocrinology. 2005 Apr;146(4):1956-64 [15637289.001]
  • [Cites] J Clin Endocrinol Metab. 1992 Oct;75(4):1060-5 [1400871.001]
  • [Cites] Clin Exp Immunol. 2008 Jan;151(1):76-85 [17983444.001]
  • [Cites] Calcif Tissue Int. 1998 Nov;63(5):369-74 [9799819.001]
  • [Cites] Atherosclerosis. 2009 Jul;205(1):255-60 [19091317.001]
  • [Cites] Endocrinol Nutr. 2009 Apr;56(4):164-9 [19627732.001]
  • [Cites] JAMA. 2006 Dec 20;296(23):2832-8 [17179460.001]
  • [Cites] J Clin Oncol. 2009 May 1;27(13):2117-9 [19349538.001]
  • [Cites] Osteoporos Int. 2009 Jan;20(1):133-40 [18458986.001]
  • [Cites] Arch Dermatol. 1991 Apr;127(4):536-8 [1848745.001]
  • [Cites] J Clin Endocrinol Metab. 2008 Jul;93(7):2693-701 [18445674.001]
  • [Cites] J Bone Miner Res. 1995 May;10(5):711-5 [7639106.001]
  • [Cites] J Bone Miner Res. 1998 Oct;13(10):1602-12 [9783549.001]
  • [Cites] Eur J Clin Nutr. 2005 Apr;59(4):533-41 [15714215.001]
  • [Cites] Environ Health Perspect. 2007 Aug;115(8):1132-9 [17687438.001]
  • [Cites] Bone. 2002 May;30(5):771-7 [11996918.001]
  • [Cites] N Engl J Med. 1998 Mar 19;338(12):777-83 [9504937.001]
  • [Cites] J Bone Miner Res. 2001 Nov;16(11):1962-71 [11697792.001]
  • [Cites] Pediatrics. 2008 Aug;122(2):398-417 [18676559.001]
  • [Cites] J Neurol. 2009 Sep;256(9):1468-79 [19399382.001]
  • [Cites] Eur J Clin Nutr. 1999 Sep;53(9):746-51 [10509773.001]
  • [Cites] JAMA. 1992 Nov 4;268(17):2403-8 [1404797.001]
  • [Cites] Curr Med Chem. 2010;17(5):453-66 [20015037.001]
  • [Cites] Arch Pediatr Adolesc Med. 2005 Apr;159(4):335-41 [15809385.001]
  • [Cites] Arch Dis Child. 2008 Jun;93(6):512-7 [18339654.001]
  • [Cites] J Nutr. 2005 Nov;135(11):2735S-8S [16251640.001]
  • [Cites] Bone. 1995 Dec;17(6):513-6 [8835303.001]
  • [Cites] J Bone Miner Res. 1996 Oct;11(10 ):1545-56 [8889856.001]
  • [Cites] Calcif Tissue Int. 2007 Nov;81(5):352-63 [17989943.001]
  • [Cites] Maturitas. 2009 Mar 20;62(3):248-62 [19211206.001]
  • [Cites] Maturitas. 2007 Oct 20;58(2):117-37 [17604580.001]
  • [Cites] Aten Primaria. 2008 Aug;40(8):393-9 [18755099.001]
  • [Cites] Diabetologia. 2008 Aug;51(8):1391-8 [18548227.001]
  • [Cites] J Clin Endocrinol Metab. 2009 Jan;94(1):26-34 [18854395.001]
  • [Cites] J Clin Endocrinol Metab. 2009 Feb;94(2):559-63 [19033372.001]
  • [Cites] Reprod Sci. 2009 Jan;16(1):7-19 [19144887.001]
  • [Cites] J Nutr. 2009 May;139(5):1002-7 [19321588.001]
  • [Cites] Am J Clin Nutr. 1998 Oct;68(4):854-8 [9771862.001]
  • [Cites] Ann Trop Paediatr. 2006 Mar;26(1):1-16 [16494699.001]
  • [Cites] Am J Clin Nutr. 2008 Apr;87(4):1039-44 [18400729.001]
  • [Cites] Photochem Photobiol Sci. 2004 Nov-Dec;3(11-12):1067-70 [15570398.001]
  • [Cites] Osteoporos Int. 2001;12(10):875-9 [11716192.001]
  • [Cites] Gynecol Endocrinol. 2007 Jan;23(1):13-24 [17484507.001]
  • [Cites] Cell Mol Neurobiol. 2010 Mar;30(2):161-71 [19774457.001]
  • [Cites] Arch Dis Child. 2004 Aug;89(8):781-4 [15269083.001]
  • [Cites] J Adolesc Health. 2005 Jul;37(1):75 [15963911.001]
  • [Cites] Diabetologia. 2004 Mar;47(3):451-62 [14758446.001]
  • [Cites] Am J Geriatr Psychiatry. 2006 Dec;14(12):1032-40 [17138809.001]
  • [Cites] Clin Chem. 2009 Jun;55(6):1163-70 [19359534.001]
  • [Cites] Osteoporos Int. 2006;17 (3):433-40 [16362145.001]
  • [Cites] Neurology. 2010 Jan 5;74(1):27-32 [19794127.001]
  • [Cites] J Nutr. 2005 Nov;135(11):2602-8 [16251618.001]
  • [Cites] J Immunol. 2009 Apr 1;182(7):4289-95 [19299728.001]
  • [Cites] J Clin Endocrinol Metab. 1991 Sep;73(3):555-63 [1874933.001]
  • [Cites] J Clin Endocrinol Metab. 2009 Jan;94(1):67-73 [18984659.001]
  • [Cites] J Steroid Biochem Mol Biol. 2004 May;89-90(1-5):491-5 [15225826.001]
  • [Cites] Pediatrics. 2009 Mar;123(3):797-803 [19255005.001]
  • [Cites] J Clin Endocrinol Metab. 1992 Oct;75(4):1099-103 [1328275.001]
  • [Cites] J Geriatr Psychiatry Neurol. 2009 Sep;22(3):188-95 [19073839.001]
  • [Cites] Pediatrics. 2001 Apr;107(4):E53 [11335774.001]
  • [Cites] Nature. 1973 Aug 24;244(5417):515-7 [4621128.001]
  • [Cites] Eur J Endocrinol. 2007 Aug;157(2):225-32 [17656603.001]
  • [Cites] J Trop Pediatr. 2004 Dec;50(6):364-8 [15537725.001]
  • [Cites] Child Care Health Dev. 2008 Mar;34(2):276-8 [18257797.001]
  • [Cites] J Nutr. 2006 Apr;136(4):1130-4 [16549494.001]
  • [Cites] Clin Chem. 2002 Oct;48(10):1731-8 [12324490.001]
  • [Cites] Am J Clin Nutr. 2003 Sep;78(3):485-92 [12936933.001]
  • [Cites] Osteoporos Int. 2005 Jan;16(1):109-13 [15175848.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 2009 Jul;80(7):722-9 [19460797.001]
  • [Cites] Am J Clin Nutr. 2009 Sep;90(3):459-67 [19640956.001]
  • [Cites] Bone. 2009 Sep;45(3):423-6 [19465168.001]
  • [Cites] Am J Clin Nutr. 2007 Jul;86(1):150-8 [17616775.001]
  • [Cites] Am J Clin Nutr. 2004 Dec;80(6 Suppl):1748S-51S [15585799.001]
  • [Cites] J Clin Endocrinol Metab. 2000 Jul;85(7):2370-7 [10902781.001]
  • [Cites] Am J Clin Nutr. 2001 Aug;74(2):206-10 [11470722.001]
  • [Cites] J Pediatr. 2009 Jan;154(1):132-4 [19187735.001]
  • [Cites] Circulation. 2008 Jan 29;117(4):503-11 [18180395.001]
  • (PMID = 28028383.001).
  • [Journal-full-title] Adolescent health, medicine and therapeutics
  • [ISO-abbreviation] Adolesc Health Med Ther
  • [Language] eng
  • [Publication-type] Review; Journal Article
  • [Publication-country] New Zealand
  • [Keywords] NOTNLM ; Vitamin D / balanced diet / osteomalacia / osteoporosis supplements / rickets
  •  go-up   go-down


61. Raizer JJ, Grimm S, Rice L, Muro K, Chandler J, Tellez C, Mellot AL, Newman S, Nicholas MK, Chamberlain M: A phase II trial of single-agent bevacizumab given every 3 weeks for recurrent malignant gliomas. J Clin Oncol; 2009 May 20;27(15_suppl):2044

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Inclusion criteria required > 18 year of age, KPS > 60, on a non-enzyme inducing anticonvulsant, adequate bone marrow, liver and renal function, and normal urine protein and creatinine.
  • Patients were assessed using Macdonald criteria and continued on trial until tumor progression or toxicity.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964646.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


62. Tomasevic Z, Radosevic-Jelic L, Tomasevic ZM, Jelic S, Milovanovic Z: Late relapse in triple negative breast cancer. J Clin Oncol; 2009 May 20;27(15_suppl):e12022

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Although triple negative status carries grave prognosis, recent data suggests that it is mostly due to high relapse rate in first 2-3 years following initial diagnosis.
  • Late relapse is determined as contra-lateral BC, loco-regional relapse, or any distant metastases at least 5 years after initial diagnosis of BC.
  • None of these pts had liver, lung, or brain metastases.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964302.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


63. Johnson ED, Tannir NN, Olejeme KA, Logothetis CJ, Jonasch E: Survival benefit in bevacizumab-based therapy in sickle cell trait patients diagnosed with renal medullary carcinoma. J Clin Oncol; 2009 May 20;27(15_suppl):e16096

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : e16096 Background: Renal medullary carcinoma (RMC) is an epithelial malignant tumor arising from collecting duct epithelium.
  • The tumor is almost exclusive to young black patients with the sickle cell hemoglobinopathies, primarily sickle cell trait.
  • This is a rare and highly aggressive tumor that is shown to be most resistant to chemotherapy.
  • Distant sites included bone, liver or lungs.
  • Future studies, including genetic studies on the tumor types are essential to determining the SNP profiles of renal cell carcinoma in black patients.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963088.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


64. Desai K, Bhattacharya S, Srirajaskanthan R, Morgan-Rowe L, Toumpanakis C, Meyer T, Caplin M: Analysis of association between carcinoid heart disease and mesenteric fibrosis in patients with midgut carcinoid tumour. J Clin Oncol; 2009 May 20;27(15_suppl):e15650

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Analysis of association between carcinoid heart disease and mesenteric fibrosis in patients with midgut carcinoid tumour.
  • The most accepted theory relating to development of heart disease is secretion of serotonin (5- hydroxy tryptamine) by the tumour or metastases.
  • METHODS: We analysed retrospectively all patients (n=200) who had metastatic (liver metatstasis) neuroendocrine tumour and carcinoid syndrome with the primary clearly identified within the small bowel or caecum.
  • CONCLUSIONS: Carcinoid heart disease and mesenteric fibrosis (and its effects) are important determinants in morbidity and mortality of patients with midgut neuroendocrine tumour.
  • Although carcinoid heart disease and mesenteric fibrosis are part of the same patho-physiologic process affecting patients with midgut neuroendocrine tumour, the results suggest that progression of these complications is independent of each other.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962789.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


65. Cardona Zorrilla AF, Moran T, Reguart N, Porta R, Queralt C, Cardenal F, Carrasco-Chaumel E, Massuti B, Taron M, Rosell R: Characteristics and outcomes of non-small cell lung cancer (NSCLC) patients (pts) carrying epidermal growth factor receptor (EGFR) mutations who progress after initial erlotinib (E) response. J Clin Oncol; 2009 May 20;27(15_suppl):8064

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • 35 pts (63%) were PS ≤2; main metastasis sites were lung (39/71%), bone (21/38%) and liver (10/18%).
  • Mutations in tumor were: 65% DelE19 (Δ746-750), 35% L858R mutation; with 31% and 20% serum detection respectively.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962639.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


66. Pineda C, Cadogan KV, Cadogan MA: Distribution of metastases in NSCLC: Economic impact of imaging. J Clin Oncol; 2009 May 20;27(15_suppl):e19036

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This compares with 42 patients with adrenal metastases, 81 with liver metastases, 80 with bone metastases, 112 with hilar adenopathy, and 159 with mediastinal adenopathy. (See Table ) Conclusions: The cost of a CT of the pelvis varies, but is estimated at approximately $2000[Fred, Herbert L., MD, MACP.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962121.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


67. Yee L, Burris HA, Kozloff M, Wainberg Z, Pao M, Skettino S, Novotny W, Durbin B, Weston J, Hurwitz H: Phase Ib study of recombinant human Apo2L/TRAIL plus irinotecan and cetuximab or FOLFIRI in metastatic colorectal cancer (mCRC) patients (pts): Preliminary results. J Clin Oncol; 2009 May 20;27(15_suppl):4129

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : 4129 Background: Preclinical data suggest that recombinant human Apo2 ligand/TNF-related apoptosis-inducing ligand (rhApo2L/TRAIL) induces tumor cell death through pro-apoptotic receptors DR4 and DR5.
  • In specific mouse xenograft colon cancer models, tumors regressed in the majority of mice given rhApo2L/TRAIL and irinotecan.
  • 2 pts (1 with progressive liver disease) discontinued therapy due to elevated ALT.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961238.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


68. Munster PN, Lacevic M, Thomas S, Christian C, Ismail-Khan R, Melisko M, Rugo H, Minton SE: Phase II trial of the histone deacetylase inhibitor, vorinostat, to restore hormone sensitivity to the antiestrogen tamoxifen in patients with advanced breast cancer who progressed on prior hormone therapy. J Clin Oncol; 2009 May 20;27(15_suppl):1075

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Other grade 3/4 toxicities included fatigue (5/29, 17%), anorexia (2/29, 7%), diarrhea (1/29, 3%), nausea/vomiting (3/29, 10%), hypokalemia (1/29, 3%), liver enzyme elevation (1/29, 3%), lymphopenia (5/29, 17%) and leukopenia (4/29, 13%).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961209.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


69. Levine MN, Deitchman D, Julian J, Liebman H, Escalante C, O'Brien MC, Ramirez L, Weise-Kelly L, Solymoss S: A randomized phase II trial of a new anticoagulant, apixaban, in metastatic cancer. J Clin Oncol; 2009 May 20;27(15_suppl):e20514

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • 23% had liver metastases.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960918.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


70. Larbaoui B: Preoperative concomitant chemoradiotherapy with capecitabine in locally advanced rectal carcinoma. J Clin Oncol; 2009 May 20;27(15_suppl):e15134

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The primary endpoint of this phase II trial was pathologic tumor response.
  • METHODS: Inclusion criteria: rectal adenocarcinoma <12 cms from anal verge, clinical stage T3-4, adequate renal, hematological and liver function.
  • Tumor location (from anal verge): < 6 cm in 8pts, >6 cm in 7pts.
  • Tumor down staging was observed in 9pts (60%), including 5pts with complete pathological response (33.3%).
  • CONCLUSIONS: Preliminary results show that preoperative concomitant chemoradiotherapy with Capecitabine is an effective regimen with an acceptable safety profile for locally advanced rectal cancer, leading to a high probability of tumor downstaging.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27960909.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


71. Aoki T, Hui H, Umehara Y, Licalzi S, Demetriou AA, Rozga J, Perfetti R: Intrasplenic Transplantation of Encapsulated Genetically Engineered Mouse Insulinoma Cells Reverses Streptozotocin-Induced Diabetes in Rats. Cell Transplant; 2005 Jul;14(6):411-421

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Excellent survival and function of the transplanted cells was due to the fact that the cells were separated from the bloodstream by the immunoisolatory membrane only and insulin was delivered directly to the liver (i.e., in a physiological manner).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28876105.001).
  • [ISSN] 1555-3892
  • [Journal-full-title] Cell transplantation
  • [ISO-abbreviation] Cell Transplant
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; Diabetes / Encapsulation / Insulin / Insulinoma cells / Pancreatic islets / Streptozotocin / Transplantation technique
  •  go-up   go-down


72. Gómez-Lechón MJ, Lahoz A, Jimenez N, Bonora A, Castell JV, Donato MT: Evaluation of Drug-Metabolizing and Functional Competence of Human Hepatocytes Incubated under Hypothermia in Different Media for Clinical Infusion. Cell Transplant; 2008 Aug;17(8):887-897

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Hepatocyte transplantation has been proposed as a method to support patients with liver insufficiency.
  • The main sources of tissue for hepatocyte isolation are marginal livers that are unsuitable for transplantation, and segments from reduced cadaveric grafts.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28871883.001).
  • [ISSN] 1555-3892
  • [Journal-full-title] Cell transplantation
  • [ISO-abbreviation] Cell Transplant
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; Apoptosis / Glycogen / Hepatocytes / Hypothermia / Infusion medium / N-Acetyl-cystein / P450 enzymes / Ureogenesis
  •  go-up   go-down


73. Aristophanous M, Penney BC, Pelizzari CA: The development and testing of a digital PET phantom for the evaluation of tumor volume segmentation techniques. Med Phys; 2008 Jul;35(7Part1):3331-3342

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The development and testing of a digital PET phantom for the evaluation of tumor volume segmentation techniques.
  • Methods for accurate tumor volume segmentation of positron emission tomography (PET) images have been under investigation in recent years partly as a result of the increased use of PET in radiation treatment planning (RTP).
  • The authors have constructed a digital tumor phantom to address this need.
  • Synthetic tumors were placed in the lung of the Zubal phantom to provide the targets for segmentation.
  • The authors measured statistical quantities to compare image intensity distributions from regions-of-interest (ROIs) placed in the liver, the lungs, and tumors in phantom and clinical reconstructions.
  • Finally, they investigate and quantify the relationship between the threshold required to segment a tumor and the inhomogeneity of the tumor's image intensity distribution.
  • The tests and various measurements performed in this study demonstrate how the phantom can offer a reliable way of testing and investigating tumor volume segmentation in PET.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2008 American Association of Physicists in Medicine.
  • (PMID = 28513024.001).
  • [ISSN] 2473-4209
  • [Journal-full-title] Medical physics
  • [ISO-abbreviation] Med Phys
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; Anatomy / Cancer / Computed tomography / Computer software / Design / General statistical methods / Liver / Lungs / Medical image noise / Medical imaging / Positron emission tomography / Positron emission tomography (PET) / Segmentation / Semiconductor device fabrication / cancer / digital phantom / image segmentation / image texture / lung / medical image processing / phantoms / positron emission tomography / radiation therapy / statistical analysis / tumor volume segmentation / tumours
  •  go-up   go-down


74. Coelingh Bennink HJT, Singer C, Simoncini T, Genazzani AR, Holinka CF, Kubista E: Estetrol, a pregnancy-specific human steroid, prevents and suppresses mammary tumor growth in a rat model. Climacteric; 2008;11(sup1):29

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Estetrol, a pregnancy-specific human steroid, prevents and suppresses mammary tumor growth in a rat model.
  • Estetrol (E<sub>4</sub>) is a pregnancy-specific D-ring metabolite of estradiol (E<sub>2</sub>) and estriol (E<sub>3</sub>) produced by the human fetal liver and present in both male and female fetuses.
  • We report that E<sub>4</sub>, dose-dependently, prevents the growth of chemically induced (7,12-dimethylbenz(a)anthracene, DMBA) mammary tumors in female Sprague-Dawley rats and that E<sub>4</sub> has the potential to reduce the number and size of pre-existing mammary tumors.
  • Rats treated with DMBA develop estrogen-responsive breast tumors.
  • This model has become the standard pharmacological model to investigate the effect of new compounds on breast tumors.
  • When DMBA-induced rats were co-treated with E<sub>4</sub> for 8 weeks, this resulted in a dose-dependent reduction in the number and size of tumors, an effect that appeared equally effective as tamoxifen treatment or ovariectomy and was not seen with ethinylestradiol.
  • When E<sub>4</sub> was administered to rats in which tumors had already developed, a significant decrease in the number and size of tumors was observed after 4 weeks.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28485647.001).
  • [ISSN] 1473-0804
  • [Journal-full-title] Climacteric : the journal of the International Menopause Society
  • [ISO-abbreviation] Climacteric
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Keywords] NOTNLM ; BREAST TUMOR / DMBA / E4 / ESTETROL / PREVENTION / TREATMENT
  •  go-up   go-down


75. Sauk J, Jensen DM, Mohanty SR, Reau N, Reddy KG, Te HS: Lack of Efficacy of Pegylated Interferon Monotherapy for Hepatitis C in Patients With End-Stage Renal Disease on Dialysis. Gastroenterol Hepatol (N Y); 2006 Jul;2(7):504-508

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Four patients (30%) had bridging fibrosis or cirrhosis on liver biopsy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Rom J Gastroenterol. 2004 Jun;13(2):99-102 [15229772.001]
  • [Cites] Curr Gastroenterol Rep. 2004 Feb;6(1):66-70 [14720456.001]
  • [Cites] Hepatology. 1999 Jan;29(1):257-63 [9862875.001]
  • [Cites] N Engl J Med. 1998 Nov 19;339(21):1485-92 [9819446.001]
  • [Cites] Nephrol Dial Transplant. 2005 May;20(5):991-3 [15741205.001]
  • [Cites] Aliment Pharmacol Ther. 2004 Jul 1;20(1):123-4; author reply 124 [15225179.001]
  • [Cites] J Hepatol. 1995 Jun;22(6):696-9 [7560864.001]
  • [Cites] Nephrol Dial Transplant. 2001 Jan;16(1):193-5 [11209032.001]
  • [Cites] J Clin Pharmacol. 2002 Oct;42(10 ):1109-15 [12362925.001]
  • [Cites] Lancet. 1998 Oct 31;352(9138):1426-32 [9807989.001]
  • [Cites] Aliment Pharmacol Ther. 2003 Dec;18(11-12):1071-81 [14653826.001]
  • [Cites] Clin Nephrol. 2005 Mar;63(3):232-5 [15786827.001]
  • [Cites] Lancet. 2001 Sep 22;358(9286):958-65 [11583749.001]
  • [Cites] Hepatology. 2004 Jun;39(6):1702-8 [15185312.001]
  • [Cites] Nephrol Dial Transplant. 1996;11 Suppl 4:46-7 [8918753.001]
  • [Cites] J Am Soc Nephrol. 1998 Dec;9(12 ):2344-8 [9848789.001]
  • [Cites] N Engl J Med. 2001 Jul 5;345(1):41-52 [11439948.001]
  • [Cites] N Engl J Med. 2004 May 27;350(22):2265-71 [15163776.001]
  • [Cites] Am J Gastroenterol. 2003 Jul;98(7):1610-5 [12873587.001]
  • [Cites] Int J Artif Organs. 1990 Nov;13(11):737-41 [2128485.001]
  • [Cites] J Hepatol. 1999;31 Suppl 1:107-12 [10622571.001]
  • [Cites] Transplantation. 1998 Mar 15;65(5):667-70 [9521201.001]
  • [Cites] Am J Kidney Dis. 2005 Apr;45(4):684-9 [15806471.001]
  • [Cites] Clin Gastroenterol Hepatol. 2005 Oct;3(10 Suppl 2):S113-7 [16234057.001]
  • [Cites] Am J Kidney Dis. 1993 Dec;22(6):822-8 [7504404.001]
  • [Cites] Transplant Proc. 1998 Aug;30(5):2070-2 [9723395.001]
  • [Cites] Semin Liver Dis. 2004;24 Suppl 2:69-77 [15346249.001]
  • [Cites] N Engl J Med. 2000 Dec 7;343 (23 ):1673-80 [11106716.001]
  • [Cites] Nephron. 1992;61(3):307-8 [1323776.001]
  • [Cites] Transplantation. 1991 Nov;52(5):810-3 [1949165.001]
  • [Cites] Am J Transplant. 2005 Jun;5(6):1452-61 [15888054.001]
  • [Cites] Am J Kidney Dis. 1998 Oct;32(4):629-34 [9774125.001]
  • [Cites] Clin Pharmacokinet. 1990 Nov;19(5):390-9 [1702693.001]
  • [Cites] Nephrol Dial Transplant. 1996;11 Suppl 4:48-51 [8918754.001]
  • [Cites] Hepatology. 2002 Jul;36(1):3-10 [12085342.001]
  • [Cites] J Am Soc Nephrol. 2000 Oct;11(10):1896-902 [11004221.001]
  • [Cites] Aliment Pharmacol Ther. 2004 Dec;20(11-12):1271-7 [15606388.001]
  • [Cites] Curr Opin Nephrol Hypertens. 1998 Sep;7(5):557-62 [9818204.001]
  • [Cites] Br J Clin Pharmacol. 1999 Apr;47(4):365-71 [10233199.001]
  • [Cites] N Engl J Med. 2000 Dec 7;343 (23 ):1666-72 [11106715.001]
  • [Cites] Nephrol Dial Transplant. 1996 Nov;11(11):2265-8 [8941588.001]
  • [Cites] Semin Dial. 2004 Jul-Aug;17(4):310-9 [15250925.001]
  • [Cites] Am J Transplant. 2001 Jul;1(2):179-84 [12099367.001]
  • [Cites] Clin Pharmacol Ther. 2000 Nov;68(5):556-67 [11103758.001]
  • [Cites] Nephron. 1998 Sep;80(1):51-6 [9730703.001]
  • [Cites] J Viral Hepat. 2001 Jul;8(4):287-92 [11454181.001]
  • [Cites] Clin Nephrol. 1992 Jul;38(1):44-8 [1499168.001]
  • (PMID = 28289353.001).
  • [ISSN] 1554-7914
  • [Journal-full-title] Gastroenterology & hepatology
  • [ISO-abbreviation] Gastroenterol Hepatol (N Y)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; Hepatitis C / dialysis / end-stage / pegylated interferon / renal disease / renal failure
  •  go-up   go-down


81. Dankwah-Quansah MA, Gutin P, Bilsky M, Huse J, Rosenblum M, Abrey LE, DeAngelis L, Omuro A: Patterns of care and outcomes in patients with intracranial hemangiopericytomas: The Memorial Sloan-Kettering Cancer Center (MSKCC) experience. J Clin Oncol; 2009 May 20;27(15_suppl):e13011

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : e13011 Background: Intracranial hemangiopericytomas are rare primary brain tumors with a tendency to metastasize.
  • Metastatic sites throughout disease course included lungs in 7 patients, bone in 10, liver in 3 and chest wall in 2.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962846.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


82. Sakaria SS, Dhanasekaran R, Pankonin M, Parekh S, Kauh JS, Kim HS: Locoregional therapies as a bridge to transplant in patients with hepatocellular carcinoma. J Clin Oncol; 2009 May 20;27(15_suppl):e15608

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • : e15608 Background: Orthotopic liver transplantation (OLT) has been widely established as the definitive treatment for patients with HCC who fit within the Milan criteria.
  • The limited availability of donor organs results in prolonged waiting periods leading to tumor progression and potential disqualification for OLT.
  • As a result, there has been a rising interest in locoregional therapies that may stall tumor progression until a donor organ is available for transplantation.
  • METHODS: We reviewed patients with a diagnosis of HCC on the transplant list between 1998 and 2008.
  • The reasons for drop-out from the transplant list included tumor progression (4.2%); condition deteriorated (11.1%); death (6.9%); refusal of transplant (2.7%); other causes (4.2%).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962686.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


83. Kuyama S, Segawa Y, Nogami N, Kiura K, Takigawa N, Shibayama T, Hosokawa S, Aoe K, Tabata M, Tanimoto M, Okayama Lung Cancer Study Group: A phase II trial of combination chemotherapy with irinotecan and amrubicin in pretreated patients with non-small cell lung cancer (NSCLC): Results of Okayama Lung Cancer Study Group Trial 0402. J Clin Oncol; 2009 May 20;27(15_suppl):e19029

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Other grade 3 or greater non-hematological toxicities included diarrhea, vomiting, pneumonitis, liver dysfunction in 4, 1, 1 and 2 patients, respectively.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962553.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


84. Nakamura K, Yamaguchi T, Sudo K, Hara T, Denda T, Azemoto R, Ishihara T, Tsuyuguchi T: A phase II trial of oral S-1 combined with gemcitabine in patients with unresectable biliary tract cancer. J Clin Oncol; 2009 May 20;27(15_suppl):e15527

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Eligibility criteria were pathologically-proven biliary tract cancer, appropriate performance status 0 to 2, age 20 to 79 years, adequate hematological, renal and liver functions, no prior chemotherapy, and written informed consent.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962258.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


85. Hess D, Boehm S, Delmonte A, Gallerani E, Barbieri P, Pace S, Carminati P, Marsoni S, Coceani N, Sessa C: Clinical development of namitecan (ST1968), a novel camptothecin derivative with high antitumor activity: Phase I clinical data. J Clin Oncol; 2009 May 20;27(15_suppl):2570

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Aim of this trial was to determine safety, PK profile and activity in adult patients with advanced solid tumors.
  • Dose limiting toxicity (DLT) definitions were: ANC <0.5x10<sup>9</sup>/L for >5 days; PLT ≥ Grade 3 (CTC V3); grade ≥2 liver/renal toxicity not recovered by D22; any non-hematologic toxicity ≥ Grade 3; D8 dose skipping due to toxicity.
  • PK was linear and data suggest an entero-hepatic recirculation.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961898.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


86. Tsikitis VL, Malireddy K, Green EA, Christensen B, Whelan R, Hyder J, Lauter D, Marcello P, Larach S, Sargent D, Nelson H: Postoperative surveillance recommendations for early-stage colon cancer based on results from the clinical outcomes of surgical therapy trial. J Clin Oncol; 2009 May 20;27(15_suppl):4013

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Sites of first recurrence did not significantly differ between late and early stage disease: liver (37.4% vs. 27.2%); lung (29.7% vs.23.6%); intraabdominal (24.2% vs.10.9%); and locoregional (12.1% vs.10.9%).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961505.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


87. Koussis H, Scola A, Maruzzo M, Ghiotto C, Orvieto E, Bozza F, Zavagno G, Jirillo A: Triple negative breast cancer: Adjuvant treatment and outcome of 62 patients. J Clin Oncol; 2009 May 20;27(15_suppl):e11636

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • They are high risk in view of poorly differentiated tumor shortened survival, younger age, increased mortality rate in the first 5 years, increased risk of brain metastasis, rapid progression from distant recurrence to death of patients.
  • To provide further insight we have undertaken a comprehensive multi year review of demographics tumor features adjuvant treatment and outcomes in this patients group.
  • The median age at diagnosis was 57 years (range 27-86 yrs).
  • The stage of the disease at diagnosis was: I in 22, IIA in 22, IIB in 8, IIIA in 4, IIIB in 2 and stage 0 in 4 patients.
  • The pattern of disease spread was: local recurrence 5, lymph node 1, liver 2 patients.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961189.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


88. Viudez A, Zárate R, Garrido M, Rodríguez J, Chopitea A, Fernández-Troconiz I, Pardo F, García-Foncillas J: Dose escalation of capecitabine in combination with biweekly cetuximab and hepatic arterial infusion (HAI) of oxaliplatin in patients with liver metastases of colorectal cancer: Preliminary clinical results. J Clin Oncol; 2009 May 20;27(15_suppl):e15080

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dose escalation of capecitabine in combination with biweekly cetuximab and hepatic arterial infusion (HAI) of oxaliplatin in patients with liver metastases of colorectal cancer: Preliminary clinical results.
  • : e15080 Background: To determine the maximum-tolerated dose (MTD) and the doses-limiting-toxicities (DLT) of concurrent capecitabine and cetuximab plus HAI of oxaliplatin (LOHP) in patients with hepatic metastases from colorectal cancer (CCR).
  • Disease progression occurred in 15 pts (78.9%; 3 pts in liver only; 4 pts with extrahepatic metastases; 8 cases with both, hepatic and extrahepatic disease).
  • DLT and MTD were established in DL4 (two pts with diarrhoea grade IV with one of them with grade III HFS) Conclusions: Combination therapy with HAI LOHP plus concurrent capecitabine and cetuximab, can be safely administered to patients with liver metastases from CCR.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964549.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


89. Chaturvedi P, George S, John A: Preventive and protective effects of wild basil in ethanol-induced liver toxicity in rats. Br J Biomed Sci; 2007 Jan;64(1):10-12

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preventive and protective effects of wild basil in ethanol-induced liver toxicity in rats.
  • This study shows that O. gratissimum prevents free radical damage to the liver and thus protects the organ from oxidative stress.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28700888.001).
  • [ISSN] 0967-4845
  • [Journal-full-title] British journal of biomedical science
  • [ISO-abbreviation] Br. J. Biomed. Sci.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Keywords] NOTNLM ; Alanine transaminase / Ascorbic acid / Aspartate aminotransferases / Catalase / Ethanol / Glutathione / Ocimum / Thiobarbituric acid
  •  go-up   go-down


90. Álvarez-Mercado AI, Sáez-Lara MJ, García-Mediavilla MV, Sánchez-Campos S, Abadía F, Cabello-Donayre M, Gil Á, Gonzalez-Gallego J, Fontana L: Xenotransplantation of Human Umbilical Cord Blood Mononuclear Cells to Rats with D-Galactosamine-Induced Hepatitis. Cell Transplant; 2008 Jul;17(7):845-857

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The aim of this study was to investigate whether human umbilical cord blood mononuclear (HUCBM) cells might be valuable in hepatic regenerative medicine.
  • Liver histology and biochemical markers of hepatic damage were determined.
  • Presence of human cells was detected in blood and liver of both control and D-galactosamine-treated animals.
  • Cell transplantation produced an improvement in both the histological damage and liver function, as demonstrated by plasma values of alkaline phosphatase, γ-glutamyl transferase, lactate dehydrogenase, and total and direct bilirubins.
  • Results obtained suggest that HUCBM cells are capable of hepatic engraftment in this human-to-rat xenotransplant model and that transplantation of HUCBM cells may be a suitable therapy for liver disease.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28841346.001).
  • [ISSN] 1555-3892
  • [Journal-full-title] Cell transplantation
  • [ISO-abbreviation] Cell Transplant
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; D-Galactosamine / Experimental hepatitis / Human hematopoietic mononuclear cells / Umbilical cord blood / Xenotransplantation
  •  go-up   go-down


91. Cunningham SC, Spinoulas A, Carpenter KH, Wilcken B, Kuchel PW, Alexander IE: AAV2/8-mediated Correction of OTC Deficiency Is Robust in Adult but Not Neonatal Spf&lt;sup&gt;ash&lt;/sup&gt; Mice. Mol Ther; 2009 Aug;17(8):1340-1346

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Ornithine transcarbamylase (OTC) deficiency, the most common urea cycle disorder, is associated with severe hyperammonemia accompanied by a high risk of neurological damage and death in patients presenting with the neonatal-onset form.
  • Contemporary therapies, including liver transplantation, remain inadequate with considerable morbidity, justifying vigorous investigation of alternate therapies.
  • Clinical evidence suggests that as little as 3% normal enzyme activity is sufficient to ameliorate the severe neonatal phenotype, making OTC deficiency an ideal model for the development of liver-targeted gene therapy.
  • In this study, we investigated metabolic correction in neonatal and adult male OTC-deficient Spf<sup>ash</sup> mice following adeno-associated virus (AAV)2/8-mediated delivery of the murine OTC complementary DNA under the transcriptional control of a liver-specific promoter.
  • This loss of expression in the neonatal liver is the consequence of hepatocellular proliferation and presents an added challenge to human therapy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2009 The American Society of Gene & Cell Therapy. Published by Elsevier Inc. All rights reserved.
  • (PMID = 28160908.001).
  • [ISSN] 1525-0024
  • [Journal-full-title] Molecular therapy : the journal of the American Society of Gene Therapy
  • [ISO-abbreviation] Mol. Ther.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


92. Sharma A, Sharma V, Kansal L: Amelioration of lead-induced hepatotoxicity by Allium sativum extracts in Swiss albino mice. Libyan J Med; 2010 Jan;5(1):4621

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Oral treatment with lead nitrate at a dose of 50 mg/kg body weight daily for 40 days (1/45 of LD<sub>50</sub>) induced a significant increase in the levels of hepatic aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase, acid phosphatase, cholesterol, lipid peroxidation, and lead nitrate.
  • In parallel, hepatic protein levels in lead-exposed mice were significantly depleted.
  • Lead nitrate exposure also produced detrimental effects on the redox status of the liver indicated by a significant decline in the levels of liver antioxidants such as superoxide dismutase, catalase, and glutathione.
  • Histological examination of the liver also revealed pathophysiological changes in lead nitrate-exposed group and treatment with garlic improved liver histology.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28156294.001).
  • [ISSN] 1819-6357
  • [Journal-full-title] The Libyan journal of medicine
  • [ISO-abbreviation] Libyan J Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; Allium sativum / hepatotoxicity / lead / lipid peroxidation / marker enzymes / metal estimation
  •  go-up   go-down


93. Nishina K, Unno T, Uno Y, Kubodera T, Kanouchi T, Mizusawa H, Yokota T: Efficient In Vivo Delivery of siRNA to the Liver by Conjugation of α-Tocopherol. Mol Ther; 2008 Apr;16(4):734-740
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficient In Vivo Delivery of siRNA to the Liver by Conjugation of α-Tocopherol.
  • Using this new vector, intravenous injection of 2 mg/kg of Toc-siRNA, targeting apolipoprotein B (apoB), achieved efficient reduction of endogenous apoB messenger RNA (mRNA) in the liver.
  • The downregulation of apoB mRNA was confirmed by the accumulation of lipid droplets in the liver as a phenotype.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2008 The American Society of Gene Therapy. Published by Elsevier Inc. All rights reserved.
  • (PMID = 28178465.001).
  • [ISSN] 1525-0024
  • [Journal-full-title] Molecular therapy : the journal of the American Society of Gene Therapy
  • [ISO-abbreviation] Mol. Ther.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


94. Van De Kerkhove MP, Hoekstra R, Van Nooijen FC, Spoelstra FOB, Doorschodt BM, Van Wijk ACWA, Poyck PPC, Chamuleau RAFM, Van Gulik TM: Subnormothermic Preservation Maintains Viability and Function in a Porcine Hepatocyte Culture Model Simulating Bioreactor Transport. Cell Transplant; 2006 Feb;15(2):161-168

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Bioartificial liver (BAL) systems have been developed to bridge patients with acute liver failure (ALF) to liver transplantation or liver regeneration.
  • All groups were tested each day for cell damage and hepatic functions.
  • Subnormothermic culture (i.e., 15°C to 28°C) for a period of 24 h did not reduce any hepatic function and did not increase cellular damage.
  • In contrast, culture of hepatocytes in WE medium and preservation in UW solution at 4°C significantly reduced hepatic function.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28886284.001).
  • [ISSN] 1555-3892
  • [Journal-full-title] Cell transplantation
  • [ISO-abbreviation] Cell Transplant
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; Bioartificial liver / Cell function / Hepatocyte / Temperature / Transport
  •  go-up   go-down


95. Valori R: Non-alcoholic fatty liver disease: a non-problem or public health catastrophe? Frontline Gastroenterol; 2010 Oct;1(3):147-148

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-alcoholic fatty liver disease: a non-problem or public health catastrophe?

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lancet. 2010 May 8;375(9726):1624-33 [20430429.001]
  • (PMID = 28839567.001).
  • [ISSN] 2041-4137
  • [Journal-full-title] Frontline gastroenterology
  • [ISO-abbreviation] Frontline Gastroenterol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


96. Gao G, Lu Y, Calcedo R, Grant RL, Bell P, Wang L, Figueredo J, Lock M, Wilson JM: Corrigendum to "Biology of AAV Serotype Vectors in Liver-Directed Gene Transfer to Nonhuman Primates". Mol Ther; 2006 Jul;14(1):150

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Corrigendum to "Biology of AAV Serotype Vectors in Liver-Directed Gene Transfer to Nonhuman Primates".

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28192691.001).
  • [ISSN] 1525-0024
  • [Journal-full-title] Molecular therapy : the journal of the American Society of Gene Therapy
  • [ISO-abbreviation] Mol. Ther.
  • [Language] eng
  • [Publication-type] Published Erratum
  • [Publication-country] United States
  •  go-up   go-down


97. Jiao L, Apostolopoulos C, Jacob J, Johnson N, Tsim N, Habib N, Coombes R, Stebbing J: The anatomic localization of circulating tumor cells and the immediate impact of surgery and radiofrequency ablation. J Clin Oncol; 2009 May 20;27(15_suppl):e22004

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The anatomic localization of circulating tumor cells and the immediate impact of surgery and radiofrequency ablation.
  • : e22004 Background: There are few data on the impact of immediate and differing surgical interventions on circulating tumor cells (CTCs), nor their compartmentalization or localization in different anatomic vascular sites.
  • METHODS: CTCs from consecutive patients with colorectal liver metastases were quantitated prior to and immediately after open surgery, laparoscopic resection, open radiofrequency ablation (RFA) or percutaneous RFA.
  • For individuals undergoing open surgery, either hepatic resections or open RFA, CTCs were examined in both systemic and portal circulation by measuring CTCs in samples derived from the peripheral vein, an artery, the portal vein and hepatic vein.
  • RESULTS: A total of 29 consecutive patients with colorectal liver metastases were included with a median age of 55 (range 30 - 88 years).
  • CTCs were localized to the hepatic portosystemic macrocirculation with significantly greater numbers than in the systemic vasculature.
  • In patients with colorectal liver metastases, CTCs are localized to the hepatic (and probably pulmonary) macrocirculations.
  • This may explain why metastases in sites other than the liver and lungs, are infrequently observed in cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963174.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


98. Nishie M, Tateno C, Utoh R, Kohashi T, Masumoto N, Kobayashi N, Itamoto T, Tanaka N, Asahara T, Yoshizato K: Hepatocytes from Fibrotic Liver Possess High Growth Potential in Vivo. Cell Transplant; 2009 May/Jun;18(5-6):665-676

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hepatocytes from Fibrotic Liver Possess High Growth Potential in Vivo.
  • Hepatocyte transplantation is effective for treating liver failure, but healthy donors as a source of hepatocytes are quite limited.
  • The livers of patients with hepatic fibrosis could be an alternative source; however, few reports have examined the nature of hepatocytes from fibrotic livers (f-hepatocytes).
  • In this study, we compared the growth of f-hepatocytes and hepatocytes from normal livers (n-hepatocytes).
  • Both types of hepatocytes were transplanted into DPPIV<sup>-</sup> mutant Fischer rats that had been treated with retrorsine to injure the liver and were partially hepatectomized (PHx) before transplantation.
  • The colony sizes of f-hepatocytes 21 days posttransplantation were approximately three times those of n-hepatocytes.
  • These characteristics of f-hepatocytes resembled those reported for small-sized n-hepatocytes (SHs), which are highly proliferative and preferentially express a unique set of 10 SH genes.
  • The expression profile of f-hepatocytes was rather similar to that of proliferating n-hepatocytes in the regenerating liver after PHx.
  • These normal and proliferative natures of f-hepatocytes in vivo suggest the fibrotic liver as a source of hepatocytes for transplantation.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28880648.001).
  • [ISSN] 1555-3892
  • [Journal-full-title] Cell transplantation
  • [ISO-abbreviation] Cell Transplant
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; Carbon tetrachloride / Hepatectomy / Hepatocyte proliferation / Hepatocyte transplantation / Liver regeneration / Retrorsine
  •  go-up   go-down


99. Stintzing S, Hoffmann RT, Heinemann V, Kufeld M, Muacevic A: Robotic radiosurgery of liver metastases of solid tumors. J Clin Oncol; 2009 May 20;27(15_suppl):e15049

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Robotic radiosurgery of liver metastases of solid tumors.
  • : e15049 Background: The number of patients (pts) suffering from isolated liver metastases is growing.
  • We here report the therapeutic efficacy of a robotic radiosurgery device for local control of liver metastases of solid tumors.
  • METHODS: Patients with liver metastases not qualifying for surgery were treated with single session radiosurgery (24 Gy) using robotic image-guided real-time tumor tracking.
  • For inclusion into the radiosurgery treatment protocol, tumor volumes had to be smaller than 80cc.
  • Median tumor volume was 21cc (range 2.2-79.3).
  • CONCLUSIONS: Robotic radiosurgery with image-guided real-time tumor tracking of liver metastases is a new and promising treatment approach for pts not eligible for surgical resection and might enhance the possibilities of multidisciplinary oncological treatment concepts.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27964438.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


100. Chatterjee A, Bhattacharya S, Chatterjee AK, Biswas J, Mukhopadhyay B: A prospective observational clinical study involving an alternative cancer treatment, psorinum therapy, in treating stomach, gallbladder, pancreas, and liver cancers. J Clin Oncol; 2009 May 20;27(15_suppl):3050

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A prospective observational clinical study involving an alternative cancer treatment, psorinum therapy, in treating stomach, gallbladder, pancreas, and liver cancers.
  • : 3050 Background: The prospective observational clinical study was conducted to know the efficacy of an alternative cancer treatment, 'psorinum therapy,' in treating liver, gall bladder, pancreatic, and stomach cancers.
  • The primary outcome measures of the study were (1) to assess the radiological tumor response;.
  • RESULTS: 158 histopathology or cytopathology proved participants (42 of stomach, 40 of gallbladder, 44 of pancreas, and 32 of liver cancers) were included in the final analysis at the end of the study.
  • According to the RECIST criteria, complete tumor response occurred in 28 (17.72%) cases and partial tumor response occurred in 56 (35.44%) cases.
  • CONCLUSIONS: Psorinum therapy is effective in treating stomach, gallbladder, pancreas, and liver cancers.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961982.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down






Advertisement